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Abstract 
Influenza A is a highly contagious respiratory virus whose surface protein hemagglutinin 
(HA) constantly obtains mutations at its five antigenic sites. These mutations occasionally 
lead to acquisition of new N-linked glycosylation sites that may alter the antigenicity and 
virulence of influenza virus by shielding the major antigenic epitopes. Glycosylation sites 71, 
142, 144, 172, 177 and 179 have occurred in the HA globular head of the natural seasonal 
H1N1 influenza A strains and become fixed over time. The immunomodulatory role of these 
single and multiple additional N-linked glycosylation sites in the recombinant pandemic 
A/Netherlands/602/09 H1N1 (rWT) background was assessed. Hemagglutination inhibition 
(HI) assays were performed with mouse and ferret antisera to evaluate the effect of these 
additional glycosylations on the breadth of humoral immune response. Poor HI activity was 
observed with antisera from mice infected with the rWT and the recombinant virus 
glycosylated at site 144 against 14 natural seasonal H1N1 isolates that occupy variable 
glycosylations and are antigenically distant from the pandemic strain. It was shown that 
mouse antisera elicited by viruses containing an additional glycosylation at site 144 or 144-
172 were capable of cross-reacting with the rWT and a panel of recombinant mutant viruses 
with single or multiple additional glycosylations. Conversely, antiserum from mice infected 
with the rWT had a considerable loss in cross-reactivity against the viruses glycosylated at 
sites 144 or 144-172. However, antisera from ferrets infected with the 144-glycosylated or 
144-172-glycosylated viruses showed narrowed cross-reactivity against a panel of 
glycosylation mutant viruses and were not capable of neutralising the rWT, as measured by 
microneutralisation assays. Based on the observations with mouse antisera, most of the 
polyclonal activity seems to be directed against the antigenic site Sa, efficiently masked by 
glycosylation at site 144. This alters the antigenicity of the 2009 pandemic H1N1 virus by 
redirecting the focus of polyclonal response to multiple sites around the site Sa. The broad 
cross-reactivity was shown to be unique to site 144, since the breadth of polyclonal response 
elicited by other mutant viruses with single or multiple glycosylation sites was narrowed 
below homologous titres, having no activity against the viruses containing the site 144. 
Broadening the humoral immune response by incorporation of additional glycosylation sites 
provides an approach for universal, broadly reactive influenza vaccines. However, further 
validation is warranted in both animal models. 
 
Key	words:	2009 pandemic H1N1 influenza, antigenicity, antigenic site Sa, broadly reactive 
influenza vaccine, cross-reactivity, hemagglutinin, humoral immune response, influenza A, 
neutralising antibodies, N-linked glycosylation 
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Tiivistelmä 
Influenssa A on erittäin helposti tarttuva hengitystievirus, jonka pintaproteiini 
hemagglutiniinin (HA) viiteen antigeeniseen kohtaan syntyy jatkuvasti mutaatioita. Nämä 
johtavat ajoittain uusien N-liitettyjen glykosylaatiokohtien syntymiseen HA:n pallomaiseen 
päähän. Kookkaat oligosakkaridiketjut saattavat peittää viruksen tärkeät antigeeniset epitoopit 
ja täten muuttaa sen antigeenisyyttä ja taudinaiheutuskykyä. HA:n pallomaisessa päässä 
sijaitsevat aminohapot 71, 142, 144, 172, 177 ja 179 ovat esiintyneet glykosyloituneina 
kausittaisissa H1N1 influenssa A −viruksissa ajan myötä. Tässä tutkimuksessa 
rekombinanttivirusten avulla selvitettiin, miten A/Netherlands/602/09 H1N1 (rWT) 
−pandemiavirukseen lisätyt ylimääräiset N-glykosylaatiokohdat muokkaavat humoraalista 
immuunivastetta. Hiirten ja frettien antiseerumeista tutkittiin näiden rekombinanttivirusten 
aiheuttaman immuunivasteen laajuutta hemagglutiniini-inhibitio (HI)- ja 
mikroneutralisaatiotesteillä. Tutkimuksessa rWT-virusta ja 144-glykosyloitua virusta vastaan 
tuotettu hiirten sekä frettien antiseerumi reagoi huonosti kausittaisiin H1N1 influenssa A 
−viruksiin, joilla on vaihteleva glykosylaatiostatus ja jotka ovat antigeenisyydeltään hyvin 
erilaisia kun vuoden 2009 H1N1 pandemiavirus. 144- ja 144–172 –glykosyloituja viruksia 
vastaan tuotetuilla hiirten antiseerumeilla todettiin olevan laajentunut ristireaktiivisuus sekä 
rWT-virusta että kaikkia mono- ja polyglykosyloituja viruksia vastaan. Sitä vastoin muita 
glykosyloituja viruksia vastaan tuotetuilla hiiren antiseerumeilla oli kaventunut reaktiivisuus 
144-glykosyloitua virusta vastaan. Yllättäen frettien 144-virusta vastaan tuotetun 
antiseerumin ei todettu reagoivan muihin glykosyloituihin viruksiin, eikä sen myöskään 
todettu neutralisoivan rWT-virusta mikroneutralisaatiotesteissä. Hiirten antiseerumeilla 
saatujen tulosten perusteella suurin osa polyklonaalisesta immuunivasteesta näyttäisi olevan 
kohdistunut antigeeniseen kohtaan Sa, jonka glykosylaatio kohdassa 144 tehokkaasti naamioi. 
Tämä mahdollisesti muokkaa kyseisen H1N1 pandemiaviruksen antigeenisyyttä ja kohdentaa 
immuunitunnistuksen todennäköisesti Sa-alueen ympärille. Laajentuneen immuunivasteen 
todettiin olevan 144-glykosylaatiokohtaspesifinen, sillä muiden lisättyjen 
glykosylaatiokohtien − sekä yksittäisten että monen glykosylaatiokohdan yhdistelmien – 
todettiin kaventavan humoraalista immuunivastetta. Näiden virusten ei myöskään havaittu 
reagoivan 144-glykosyloituihin viruksiin. Immuunivasteen laajentaminen HA-
glykosylaatioiden avulla tarjoaa kiinnostavan lähestymistavan uudenlaisen, laajasti 
reaktiivisen influenssarokotteen kehittämiseen. Lisätutkimuksia kuitenkin tarvitaan 
molemmilla eläinmalleilla tulosten varmistamiseksi. 
Avainsanat:	 antigeenisyys, antigeeninen kohta Sa, hemagglutiniini, humoraalinen 
immuunivaste, influenssa A, laajasti reaktiivinen influenssarokote, neutralisoivat vasta-aineet, 
N-liitetty glykosylaatio, ristireaktiivisuus, vuoden 2009 H1N1 influenssapandemia 
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1 Introduction	
Influenza A viruses belong to the family Orthomyxoviridae that is divided into three 
genera: influenza A, B and C viruses, Thogotovirus and Isavirus. Influenza A and B 
viruses are responsible for the seasonal epidemic outbreaks that occur annually during 
the winter months. Influenza A is a highly contagious respiratory pathogen that is 
transmitted in close contact via aerosol droplets. It is capable of infecting the upper 
respiratory tract (URT) and lower respiratory tract (LRT) of humans and various animal 
species by binding on specific sialic acid (SA) receptors on epithelial cells via its 
surface glycoprotein hemagglutinin (HA). The classification of influenza viruses is 
based on the sequence variation in these main surface glycoproteins (Air 1981) that are 
the virion surface molecules containing the main antigenic epitopes, receptor binding 
sites and crucial enzymatic functions. 
 
Figure	 1.	 The	 two	 influenza	 A	 groups	 are	 divided	 into	 clades	 and	 subtypes.	 There	 are	 16	antigenically	characterised	influenza	A	subtypes,	all	of	which	have	been	found	circulating	in	birds.	Modified	from	(Medina	&	García-Sastre	2011).	
The HA subtypes are classified into two lineages and further into four clades, based on 
their antigenic and structural properties (Figure 1). There are 16 antigenically 
characterised influenza A HA subtypes and 9 NA subtypes, although only three HA 
subtypes (H1−H3) and two NA subtypes (N1 and N2) have been found circulating in 
humans. However, a unique bat influenza virus H17N10 of a distinct lineage has been 
very recently described (Tong et al. 2012) and seems to differ substantially from other 
HA and NA subtypes in its structural and functional characteristics (Zhu et al. 2013). 
Since the beginning of the documented medical history, rapid evolution of influenza 
viruses has been on-going in humans, birds, pigs, horses and other animal species. 
Interspecies transmission is responsible for the genetic diversity of the influenza 
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viruses. The changes that alter the antigenic properties of the seasonally circulating 
viruses are known as antigenic drift that involves minor, gradual amino acid changes 
within the antigenic regions of the HA and NA proteins. Some of these mutations alter 
the glycosylation profile of these proteins, which affects the immunogenicity and 
virulence of influenza viruses. At times the human strains undergo reassortment events 
with zoonotic subtypes. This major exchange of the gene segments between different 
species is known as antigenic shift that creates new variants with acquired new 
antigenic properties and can result in pandemics. Due to the continuous antigenic 
evolution, control of influenza virus transmission is challenging. 
Currently two influenza A subtypes, H1N1 and H3N2, are circulating in humans2 and 
causing annual epidemics. Due to cross-reactive pre-existing neutralising antibodies 
(nAbs) present in the population, the arising antigenically drifted variants commonly 
cause solely a mild self-limited respiratory disease due to their antigenic similarity with 
the previously circulating strains. Influenza A and B viruses cause tens of millions of 
human infections every year, leading to an estimated 250,000−500,000 annual deaths 
worldwide (World Health Organization 2009). The highest mortality rate of the 
seasonal influenza is seen in the elderly (> 65 years of age) that is the most susceptible 
portion of the population due to underlying morbidities (Nichol 2005, Fireman et al. 
2009). Influenza remains as the main infectious disease of the developed world with 
significant economic losses.  
This thesis gives a compact review on influenza A (H1N1) viruses based on their 
extensive antigenic variation and pandemic potential, although the importance of 
influenza B viruses on the health of the population is not to be dismissed. For more 
detail on the structural and functional properties of influenza viruses, the reader is 
kindly requested to take a look at an excellent review by Medina and García-Sastre 
(2011) and the Chapters 47 and 48 of Fields Virology (Palese & Shaw 2007, Wright et 
al. 2007). The natural influenza isolates are universally abbreviated as for instance 
A/California/7/2009 (H1N1), which means that this particular virus was an isolate 
number 7 of a human influenza A taken in California in year 2009 and it has an HA 
subtype of 1 and an NA subtype 1. This nomenclature is used throughout the thesis 
whose focus is on subtype H1N1 influenza A viruses.  
                                                          
2 
http://www.who.int/influenza/surveillance_monitoring/updates/2013_03_15_surveillance_update_181.pd
f (accessed 2.4.2013) 
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2 Review	of	the	literature	
2.1 Structure	of	the	influenza	A	virion	
 
 
Figure	2.	The	 influenza	 A	 viral	particle	with	 the	 segmented	 genome	 and	 the	 contributing	
proteins.	HA	=	hemagglutinin,	NA	=	neuraminidase,	M2	=	ion	channel	protein,	NEP/NS2	=	nuclear	export	protein,	M1	=	matrix	protein	layer,	NP	=	nuclear	protein	around	which	the	viral	RNA	(vRNA)	is	wrapped.	NP	and	vRNA	together	form	the	viral	ribonucleoprotein	(RNP)	complex	that	is	bound	to	the	viral	polymerase	complex	PA/PB1/PB2.	Modified	from	(Medina	&	García-Sastre	2011).	
Influenza A viruses are spherical or filamentous viruses with a diameter of 100 nm or 
300 nm, respectively. The virus is surrounded by a host-cell derived lipid envelope with 
five distinct proteins protruding from the lipid layer: the receptor-binding protein HA, 
the SA-destroying enzyme NA, the matrix protein M1, the ion channel M2 and the 
nuclear export protein (NEP) that is located right beneath the envelope (Figure 2). HA 
and NA proteins are the predominant surface proteins that form 10−14 nm spikes on the 
virion exterior and are present with an approximate ratio of 4:1. The eight (−) ssRNA 
segments of influenza A genome each code for one or two proteins (Table 1) (Palese 
1977). Each segment contains a non-coding region in the 5´ and 3´ ends that is partly 
segment-specific and has 13 conserved nucleotides in the 5´ end and 12 conserved 
nucleotides in the 3´ end. The segments are transcribed into mRNAs and synthesised 
into (+) strand RNA copies (cRNA) that function as templates for (−) viral genomic 
RNA (vRNA) synthesis. In addition to cRNA and mRNA synthesis, influenza A 
synthesises RNA from the M gene that gives rise to spliced mRNA and produces M2 
protein and RNA from the NS gene that produces NEP from a spliced mRNA. 
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Additionally, PA-X protein has been recently described to be expressed from an open 
reading frame (X-ORF) of segment 3 by +1 ribosomal frameshifting (Jagger et al. 2012, 
Lee et al. 2012, Shi et al. 2012). This results in production of 12 viral proteins in total.  
 
Table	 1.	 The	 genomic	 segments	 of	 an	 influenza	 A/Puerto	 Rico/8/1934	 (H1N1)	 virus	 and	
their	encoded	proteins.	The	eight	(−)	ssRNA	genomic	segments	have	variable	lengths	and	code	for	proteins	with	multiple	 functions	 in	 the	 complete	 virus	particle.	Table	modified	 from	 (Bouvier	 &	Palese	2008).	
Segment	
number	
Segment	
length	(nt)	
Encoded	
proteins	
Protein	
length	(aa)	 Protein	function	
1	 2341	 PB2	 759	 Polymerase	subunit;	mRNA	cap	recognition	
2	 2341	 PB1	 757	 Polymerase	subunit;	RNA	elongation,	endonuclease	activity	PB1-F2	 87	 Pro-apoptotic	activity	
3	 2233	 PA	 716	 Polymerase	subunit;	protease	activity	PA-X	 252	(Taubenberger	
et	al.	2005)	 Cellular	signalling,	endonuclease	activity,	viral	pathogenicity	(Jagger	et	al.	2012,	Lee	et	al.	2012)	
4	 1778	 HA	 550	 Surface	glycoprotein;	major	antigen,	receptor	binding	and	fusion	activities	
5	 1565	 NP	 498	 RNA	binding	protein;	nuclear	import	regulation	
6	 1413	 NA	 454	 Surface	glycoprotein;	sialidase	activity,	virus	release	
7	 1027	 M1	 252	 Matrix	protein;	vRNP	interaction,	RNA	nuclear	export	regulation,	viral	budding	M2	 97	 Ion	channel;	virus	uncoating	and	assembly	
8	 890	 NS1	 230	 Interferon	antagonist	protein;	regulation	of	host	gene	expression	NEP/NS2	 121	 Nuclear	export	of	RNA	
	
2.2 Influenza	life	cycle	
The viral cycle begins with the attachment of the virus HA on the SA α2,6-galactose 
β1,4-N-acetyl glucosamine (SA α-2,6Gal) or on the SA α2,3-galactose β1,3-N-acetyl 
galactosamine (SA α-2,3Gal) receptors on the host epithelial cell surface (Figure 3). 
Acidification of the inside of the virion occurs through the ion exchange channel M2, 
which initiates viral internalisation by endocytosis via clathrin-coated pits, caveolae, 
macropinocytosis or alternative internalisation methods [reviewed in (Conner & Schmid 
2003, Lakadamyali et al. 2004)] in pH 5.0−5.5 [reviewed in (White et al. 1983)]. This 
results in a simultaneous conformational change in the transmembrane domains of 
multiple HAs within the viral envelope and the fusion peptide domains located in the 
endosomal membrane, which enables the fusion of these membranes. The viral contents 
can then enter the cytoplasm where the RNPs become trafficked into the nucleus, a 
process driven by their nuclear localisation signals (NLSs). The low pH within the 
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endosome triggers the host cell driven proteolytic cleavage of the disulfide bonds 
between the HA1 and HA2 subunits and results in generation of a fusion peptide. 
 
Figure	3.	The	replication	cycle	of	influenza	A	viruses.	The	cycle	begins	with	viral	attachment	on	SA	receptors	(SA	α2,3	or	SA	α2,6)	on	the	cell	surface	via	HA.	After	the	virus	has	entered	the	cell,	the	low	pH	in	the	endosome	causes	fusion	and	uncoating	of	the	lipid	layer	–surrounded	virus.	Viral	RNA	(vRNA)	 is	trafficked	 into	the	nucleus	as	part	of	the	RNP	complex,	where	 it	 is	copied	 into	(+)	copy	RNA	 (cRNA)	 and	 amplified	 to	 be	 assembled	 into	 new	 virions.	 In	 a	 parallel	 process	 the	 cRNA	 is	transcribed	into	mRNA	and	the	viral	proteins	are	being	translated	to	be	packaged	into	new	virions.	Non-structural	proteins	NS1	and	PB1-F2	are	 involved	 in	apoptotic	and	antiviral	processes.	Figure	modified	from	(Medina	&	García-Sastre	2011).	
All RNA synthesis occurs in the host cell nucleus where the eight (−) vRNA segments 
are transcribed into mRNAs and a (+) cRNA is synthesised for replication of the 
progeny viral RNA by the viral RNA-dependent RNA polymerase. The virus uses a 
“cap-snatching” mechanism of stealing the host pre-mRNA 5´capped primers to initiate 
its own mRNA synthesis. The viral RNA-dependent RNA polymerase adds a poly (A) 
tail after it has accomplished the mRNA synthesis from the vRNA template. The 
cellular splicing machinery is used for alternative splicing of the primary transcripts and 
is highly controlled to enable production of both unspliced and spliced mRNAs. The 
initiation of replication requires a switch in the polymerase and may involve the 
presence of free NP. In the second step the (−) vRNA is first synthesised into full 
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sequence (+) cRNA by the viral RNA-dependent RNA polymerase via a primer-
independent mechanism. The cRNA is then used as a template when an encapsidated 
(−) genomic vRNA copy is produced by the same viral polymerase. The newly 
produced vRNA segments are then assembled into RNP complexes and transported into 
the cytoplasm by the M1 and NEP proteins through nuclear pores. The mRNAs are 
transported into the cytoplasm, where they are translated on the membrane-bound 
ribosomes by the cellular machinery. In ER the integral membrane proteins HA and NA 
become folded and glycosylated; HA is assembled into a trimer and NA into a tetramer. 
Later they are palmitoylated and glycosylated in the Golgi apparatus and directed along 
with the RNPs to the apical membrane of the polar epithelial cells where the assembly, 
budding and release of the mature viruses occurs. The release requires active enzymatic 
degradation of the cellular receptor SAs and viral glycoproteins by the neuraminidase 
activity of the NA.  
2.2.1 Influenza	tropism	&	transmission	route		
Influenza virus has to fight its way through physical barriers such as mucus, 
macrophages and epithelial cells, and successfully attach, enter and replicate. 
Interspecies transmission of influenza viruses has been largely facilitated by common 
habitat use, animal trade, international travel and bird migration but is further puzzled 
by genetic reassortment and recombination that may provide sudden fitness advantages 
to the virus. More about host species barriers to influenza virus is covered in an 
excellent review (Kuiken et al. 2006). The influenza virus A can potentially transmit 
from human-to-human in direct or indirect contact, via large droplets or airborne 
aerosolisation of secretions or fomites. Direct or indirect contact involves physical 
contact with the infected individual or contaminated instruments/objects, which is 
facilitated by the ability of influenza virus to remain infectious on dry surfaces for up to 
48 hours (Bean et al. 1982). The pathogens can also spread by large droplets that are 
generated from the respiratory tract of an infected individual by sneezing, coughing, 
talking or during a respiratory operation. Smaller aerosols can be generated from the 
large droplets that can remain in the air for long periods attached to dust particles or 
skin cells/debris. Aerosol transmission seems to be an important mode of transmission 
since the particles remain airborne for prolonged periods, which enables long-range 
infections. Transmission of influenza A is reviewed in (Tellier 2006, Brankston et al. 
2007). 
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The cell tropism of influenza A viruses is determined by the receptor recognition 
specificity and affinity of the HA anchored on the virion surface. Bronchial epithelial 
cells, nasal mucosa, goblet (mucous) cells, paranasal sinuses and pharynx of the human 
URT carry SA α-2,6Gal surface receptors (Ibricevic et al. 2006, Shinya et al. 2006) that 
function as primary receptors for the H1 and H3 human influenza A viruses (Rogers & 
Paulson 1983, Rogers & D'Souza 1989). In contrast, the avian H5 influenza viruses use 
the SA α-2,3Gal as their primary receptor (Connor et al. 1994) that can be found in the 
bird gut epithelium as well as on the alveolar type-II cells and non-ciliated cuboidal 
bronchiolar cells of the human LRT (Shinya et al. 2006). Pigs have both of these SA 
receptor types in their trachea, which enables simultaneous infection of swine, human 
and avian viruses and thus makes them a possible mixing vessel for genetic 
reassortment events between viruses of different zoonotic origin. The SA receptors 
recognised by influenza A viruses and the distribution of SA receptors in various hosts 
is reviewed in (Hidari & Suzuki 2010). 
Influenza A viruses are also known to infect natural killer (NK) cells, antigen-
presenting cells, macrophages, monocytes, neutrophils, respiratory dendritic cells 
(DCs), B cells, CD4+ cells and CD8+ cells (Manicassamy et al. 2010a). In this mouse 
study a fully replicating reporter virus carrying a green fluorescent protein (GFP) tag in 
its NS1 segment was produced by reverse genetics methods. This attenuated but 
pathogenic virus was shown to begin spreading from UTR and to then continue deeper 
into the lungs, eventually infecting high levels of immune cells. Mannose receptors 
have been shown to be involved in macrophage infection by influenza viruses (Reading 
et al. 2000). Two seasonal H3N2 viruses were shown to have improved infectivity of 
murine macrophages compared to a H1N1 virus. The mannose-binding lectins and lung 
surfactant protein D were shown to be involved in endocytic entry and the virus 
sensitivity to these collectins was parallel to their relative infectivity. These C-type 
lectins are known to be involved in influenza virus opsonisation (Hartshorn et al. 1994, 
Hartshorn et al. 1996), complement-dependent neutralisation (Anders et al. 1994) and 
aggregation (Hartshorn et al. 1994, Hartshorn et al. 1997) by binding to the 
oligosaccharide side chains present on the glycoproteins HA and NA. Interestingly, 
collectin-sensitivity has been shown to correlate with the number of N-linked 
glycosylations of the HA globular head and to have inverse relationship with viral 
replication in the lungs (Reading et al. 1997). The authors suggest that glycosylation 
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pattern can act as a virulence factor that determines the character of innate immune 
defences in the respiratory tract. 
 
Figure	4.	Influenza	A	host	tropism.	Influenza	viruses	infect	humans	and	animals	from	various	species,	wild	aquatic	birds	serving	as	a	ubiquitous	virus	pool.	Figure	modified	from	(Wright	et	al.	2007).	
	
Influenza A viruses have been extensively studied in various animal species and 
geographical regions and therefore a vast amount of information has been obtained on 
the evolution and ecology of RNA viruses during the last century. The first bird 
influenza virus was isolated as early as 1902, followed by isolation from pigs in 1930, 
from humans in 1933, from horses and domestic ducks in the 1950’s, from terns 1961 
and from waterfowl and shorebirds in 1974. A new influenza A subtype H17N10 was 
initially found from two bat populations in Guatemala and seems to be highly divergent 
from all known influenza A viruses, according to the preliminary characterisation 
studies (Tong et al. 2012). Bird surveillance studies have shown that aquatic birds 
provide a complete genetic reservoir and a ubiquitous source of all mammalian 
influenza virus subtypes. With this diversity they are able to infect various mammalian 
and avian species (Figure 4) at high concentrations by direct transmission via faeces to 
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different water sources. Ducks are thought to play an important role in influenza virus 
evolution and to function as a highly adapted asymptomatic reservoir for viral 
transmission to seals, whales, pigs and domestic poultry (Webster et al. 1978). More 
about the ecology of influenza can be found in an extensive review by Webster and 
colleagues (1992). 
2.3 Evolution	of	influenza	A	viruses	
2.3.1 Antigenic	drift	creates	seasonal	variation	
One of the most important characteristics of influenza A viruses is their ability to 
undergo rapid antigenic variation in high immune selection pressure, which accounts for 
their high infectivity and leads to annual human epidemics. Variation is brought up by 
substitution point mutations that are a result of the error-prone RNA polymerase lacking 
proofreading activity. This polymerase introduces an erroneous base once in every 104 
nucleotides while for DNA polymerases the error rate is as low as 1 in 109 (Holland et 
al. 1982). The viruses have undergone multiple amino acid changes over time, probably 
due to immune pressure of the pre-existing immunity and escape from the immune 
pressure of the host (Sun et al. 2011). The influenza virus undergoes unpredictable 
seasonal antigenic variation in its major surface proteins HA and NA. The most 
immunologically relevant changes occur in the five HA globular head antigenic regions 
that possess the main antigenic epitopes for humoral immune recognition.  
 
An accelerated antigenic drift model was demonstrated under immune selection 
pressure by propagating a seasonal H1N1 strain (A/Puerto Rico/8/34) in inbred 
vaccinated mice (Hensley et al. 2009). It was shown that during nine passages in 
immunized mice, three single-amino acid substitutions occurred within the four 
antigenic regions of the HA globular head. Those mutations that lead to enhanced 
receptor binding affinity also enhanced the virus escape from polyclonal antibodies. In 
contrast, when these high-avidity mutants were introduced into naïve individuals, they 
acquired additional mutations and the viruses with decreased receptor binding affinity 
got selected. Based on these results it was proposed that those amino acid changes that 
lead to increased receptor binding avidity and often to altered antigenicity alike, get 
selected in immune individuals and provide the virus a means of escaping the pressure 
of pre-existing nAbs. Rapid antigenic drift in the antigenic and receptor binding regions 
of influenza A HA impairs the efficacy of the current influenza vaccines and therefore it 
is of great importance to assess the mutations that lead to seasonal variation. 
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2.3.2 The	role	of	N-linked	glycosylations	in	antigenic	drift	
Arginine (N)-linked glycosylation is a naturally occurring post-translational process in 
various different proteins and also forms a significant part of seasonal antigenic drift of 
influenza A viruses. The level of N-linked glycosylations has been shown to modulate 
the receptor binding affinity (Ohuchi et al. 1997, Wang et al. 2009, Das et al. 2011) and 
specificity (de Vries et al. 2010) of influenza viruses and to regulate virus growth in cell 
culture (Wagner R et al. 2000), probably due to steric hindrance or electrostatic 
repulsion by the bulky oligosaccharide moieties. The impact of additional HA 
glycosylations (subtype H5) on the receptor binding affinity was determined by a 
synthetic SA glycan array by comparing the difference of free energy change between 
receptor sialosides (Wang et al. 2009). This study showed enhanced receptor binding 
affinity of monoglycosylated HA molecules to sialocides compared to their fully 
glycosylated counterparts, which is likely due to crucial 3D structure alterations and 
steric hindrance in the receptor binding pocket of the fully glycosylated viruses. 
Additionally, improved cross-reactivity of an antisera from monoglycosylated HA 
protein immunizations against H5 and H1 viruses was reported, as compared to their 
fully glycosylated counterparts.  
Glycosylations that occur in close proximity to the antigenic regions of the HA may 
alter the antigenicity (Aytay & Schulze 1991, Munk et al. 1992, Tsuchiya et al. 2002) 
and immunogenicity of the virus (Wanzeck et al. 2011). The attached host cell −derived 
oligosaccharides provide the virus an intelligent means of escape from the immune 
system since they are recognized as “self” by the host immune machinery (Schulze 
1997). HA glycosylations are also known to mask or unmask the antigenic epitopes 
from antibody (Wiley & Wilson 1981, Wiley & Skehel 1987, Schulze 1997, Das et al. 
2010) and the major histocompatibility complex recognition (Jackson et al. 1994) and 
by this means to alter the virulence and host humoral immune responses. The 
acquisition of these large oligosaccharides adjacent to the five antigenic sites and the 
receptor binding pocket helps the virus to escape antibody neutralisation by blocking 
their access to the antigenic epitopes, a method well described for the human 
immunodeficiency virus (HIV) glycoproteins (Zhang et al. 2004, Vigerust & Shepherd 
2007, Stansell & Desrosiers 2010). It has been shown that as short as maltobiose 
carbohydrate side chains on synthetic peptides can inhibit the T cell recognition, even 
outside a T cell determinant (Jackson et al. 1994). However, in that study they did not 
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seem to prevent antibody binding despite of potential steric hindrance at the peptide 
epitope.  
Glycosylations can also have detrimental effects on the viral pathogenicity by 
preventing the cleavage of HA0 into HA1 and HA2 if they occur in close proximity to 
the fusion peptide cleavage site of the stem region (Kawaoka & Webster 1988). It has 
also been observed that in comparison with the H3 HA globular head that has acquired 
an increasing number of glycosylation sites since the appearance of H3N2 in 1968, the 
H1 HA has acquired only a few glycosylations during its circulation in the human 
population (Das et al. 2010). This suggests a high selection cost for the heavily 
glycosylated viruses, probably due to diminished cell attachment, entry and/or 
replication. HA glycosylation has been shown to abolish the receptor avidity of the 
viruses and therefore the utilisation of hyperglycosylation as an immune evasion 
strategy seems to be limited (Das et al. 2011). In this study a seasonal H1N1 virus was 
able to escape from the H28-A2 monoclonal antibody neutralisation by introducing a 
substitution mutation N133T or K144N that resulted in N-linked glycosylation at site 
131 or 144, respectively. Additional compensatory mutations in HA or NA were 
observed for all the escape mutants and the receptor binding affinity of the 131 or 144 
glycosylation mutant viruses was shown to decrease by 71%, to lower than WT levels. 
These results suggest that escape from nAbs can be adjusted by receptor binding affinity 
and that accumulated glycosylations do not provide an escape mechanism for H1 type 
HA due to steric hindrance at the antigenic/receptor binding sites. It seems likely that 
the fitness cost caused by the additional glycosylations has to be compensated by 
additional mutations to retain full viral functionality. 
2.3.3 Emergence	of	strains	with	pandemic	potential	
Occasionally major genetic changes lead to virus strains that are no longer recognised 
by the overall pre-existing immunity present in the human population. Major genetic 
reassortments between the gene segments from different animal and human influenza A 
viruses have resulted in pandemic outbreaks that have been capable of infecting a large 
proportion of the human population and causing millions of deaths worldwide (Johnson 
& Mueller 2002). Gene reassortment can occur in case two viruses from different 
subgroups infect an individual simultaneously, which enables assembly of the segments 
into novel virions. These events can result in antigenic shift when virus with an 
antigenically novel HA emerges. Pre-existing neutralising immunity against this novel 
reassortant virus is likely to be very low in the human population, which correlates 
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directly with the degree of the overall disease severity. In theory, novel emerging strains 
must have the HA from a non-human virus to have the ability of evading the pre-
existing anti-HA immunity and causing a successful pandemic among the human 
population. 
2.3.4 Alterations	in	receptor	specificity	
Tissue tropism is one of the most important features of influenza virus virulence and 
transmissibility between animal and human hosts. Small-scale genomic mutations that 
lead to changes in receptor specificity have been shown to modulate the host tropism 
and transmissibility of influenza viruses. An important characteristic of a novel 
pandemic variant is its ability to spread from human-to-human, which greatly increases 
the pathogenicity of the virus due to its broadened host tropism. Pigs are known to 
function as effective mixing vessels for influenza viruses with different zoonotic origins 
due to the fact that both types of SA receptors − α-2,6Gal and α-2,3Gal − are 
represented in their respiratory tract (Rogers & D'Souza 1989).  
The mutations responsible for altered receptor specificity from SA α-2,6Gal to SA α-
2,3Gal specificity have been mapped to the residues 190 and 225 (H3 numbering) for 
the swine-origin H1 influenza viruses (Matrosovich et al. 2000, Gambaryan et al. 2005, 
Glaser et al. 2005). It has been demonstrated that only one change in these two amino 
acids within the HA receptor-binding pocket of the 1918 pandemic H1N1 influenza A 
strain (pH1N1/18) is enough to switch the binding preference from human to avian SA 
receptors (Tumpey et al. 2007). Severe or fatal cases of the 2009 pandemic H1N1 
influenza A strain (pH1N1/09) have been show to commonly carry a substitution 
mutation Asp222Gly in the HA receptor-binding site, which altered their preference 
from non-ciliated cells to ciliated bronchial epithelial cells and increased their binding 
to SA α-2,3 receptors (Chutinimitkul et al. 2010, Kilander et al. 2010, Liu et al. 2010) 
without affecting their antigenicity (Chutinimitkul et al. 2010). This was thought to be 
directly connected to the enhanced virulence and severity of the infection, although it is 
unsure whether the substitution presents a cause or a consequence of a fatal underlying 
pathology in the LRT. The HA amino acid residues related with SA receptor 
recognition is reviewed in (Hidari & Suzuki 2010). 
The highly pathogenic avian H5N1 virus has been raising concerns of a future 
devastating human pandemic [H5N1 outbreaks are reviewed in (Webster et al. 2006)]. 
Although the H5N1 virus has caused global outbreaks in Asia since 2003, its spread is 
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limited by the apparent lack of human-to-human transmission due to restricted receptor-
specificity and other factors essential for replication [reviewed in (Webster & 
Govorkova 2006)]. In order to ensure efficient human-to-human transmission, these 
viruses must gain mutations that enable SA α-2,6Gal receptor recognition and allow 
infection of the URT and efficient spread by sneezing and coughing (Shinya et al. 
2006). It is also known that avian influenza viruses H5N1, H9N2 and H7N7 infect 
ciliated cells, whereas human influenza viruses prefer non-ciliated cells for infection 
(Matrosovich et al. 2004a). However, since all influenza A viruses are constantly 
evolving, the emergence of highly contagious avian virus capable of wide human 
transmission may only be a matter of time. A recently emerged novel avian virus H7N9 
has been laboratory-confirmed in 109 Chinese citizens3, of which 22 people have died 
since the 1st of April 2013. The source of this strain is currently unidentified and no 
human-to-human transmission has been reported. For more information on the 
evolution, ecology and the origins of emerging human influenza viruses, see reviews by 
Webster and colleagues (1992) and Medina and García-Sastre (2011). 
2.3.5 Influenza	A	pandemics	of	the	past	century	
Phylogenetic studies have revealed that the human pandemic influenza viruses have 
arisen either by reassortment of avian influenza viruses with current human strains or by 
direct transmission of avian or mammalian viruses that have acquired infectivity and 
novel pathogenicity in humans [reviewed in (Webster et al. 1992)]. The reassortment 
events within the influenza A genome have contributed to antigenic escape of the novel 
viruses from the pre-existing immunity among the human population, which has led to a 
five major pandemics: the Spanish flu in 1918 (H1N1), the Asian flu in 1957 (H2N2), 
the Hong Kong flu in 1968 (H3N2), the Russian flu in 1977 (H1N1) and the most recent 
swine flu in 2009 (H1N1). In addition to the pandemic outbreaks, seasonal epidemics 
continue devastating the human population. 
The first recorded human influenza A pandemic in 1918 was caused by a highly virulent 
H1N1 virus that infected about 20−40% of the world’s population and caused an 
estimated of 50 million deaths4 worldwide. The H1N1 caused human influenza 
epidemic in 1950 after which it was replaced by the 1957 pandemic H2N2 and 
disappeared, until it again reappeared into human population in 1977. The pH1N1/18 
virus and the human H1N1 viruses that circulated until 1920 subsequently recombined 
                                                          
3 http://www.who.int/csr/don/2013_04_25/en/index.html (accessed 26.4.2013) 
4 http://www.flu.gov/pandemic/history/index.html (accessed 21.3.2013) 
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with the North American avian viruses and the human H3N2 viruses, creating a triple-
reassortant North American swine H3N2 virus that was introduced into the human 
population in 1968. These viruses further underwent a recombination with a classical 
swine virus H1N1, which resulted in a triple-reassortant North American swine H1N2. 
Between 1968 and 1977 the dominant influenza strain was H3N2, after which it has 
continued its circulation in the human population (Couch & Kasel 1983). Since the 
1977 pandemic the H1 HA globular head has acquired additional mutations and has 
been responsible for seasonal influenza epidemics until the recent outbreak in 2009 that 
most likely resulted from a recent reassortment event of the Eurasian ´avian-like´ swine 
H1N1 with the North American swine-origin influenza virus (SOIV) H1N2.  
Evolutionary analysis has shown the novel triple-reassortant pH1N1/09 SOIV virus to 
have been circulating and possibly undergoing further reassortments in the swine 
population for approximately one decade before its pandemic emergence in humans 
(Smith et al. 2009). The emergence of a novel pandemic H1N1 in humans was 
originally announced by US CDC on the 15th of April in 2009 in California (USA) as 
the virus was isolated from two epidemiologically unlinked paediatric patients (Dawood 
et al. 2009). The original report revealed that the genes of this pH1N1/09 were derived 
from the previously circulating human, swine and avian-like swine viruses (i.e. PB2 and 
PA from North American avian viruses, PB1 from the human H3N2 viruses, NA and M 
from the Eurasian ´avian-like´ swine viruses and HA, NP and NS from the classical 
swine H1N1 viruses). The genetic analyses have revealed the human pH1N1/09 to have 
low genetic diversity, which suggests that it was introduced into the human population 
in a single event or in multiple events of similar viruses (Garten et al. 2009). 
Comprehensive in vitro and in vivo studies have aimed at describing the pathogenicity, 
drug sensitivity and human antibody cross-reactivity of a pH1N1/09 isolate 
A/California/04/09 (Itoh et al. 2009). The authors report this virus to transmit among 
ferrets, to replicate efficiently in mice, ferrets and non-human primates and to cause 
severe pathological lung lesions that resemble infection with the highly pathogenic 
H5N1 viruses. However, in a pathogen-free miniature pig model the infection was non-
symptomatic although the virus replicated efficiently in the respiratory tract. In this 
study the virus was also shown to be susceptible to current approved antiviral drugs but 
to be resistant to ion channel inhibitors. It showed high cross-reactivity with the 
antigenically similar pH1N1/18 virus antisera from individuals born before the 1950’s, 
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which was consistent with a previous observation that 33%5 of the population over 60 
years of age have nAbs to pH1N1/09 due to exposure to swine-origin H1N1 viruses that 
circulated after the pH1N1/18. It is proposed that the HA of this virus remained in 
antigenic stasis in the pig population until it successfully hit the serologically 
susceptible human population and was able to cause a new pandemic.  
The symptoms of this febrile illness varied from self-limited to severe lethal infection 
involving respiratory failure and even death due to secondary infections and underlying 
chronic conditions (Dawood et al. 2009). The first estimate of global deaths due to the 
pH1N1/09 influenza virus is that it lead to more than 200,000 respiratory deaths with an 
additional 83,000 cardiovascular deaths over a period of the first 12 months (Dawood et 
al. 2012). The range of total deaths in this modelling study was estimated to be 
151,700−575,400 with 80% of the deaths within the population of < 65 years of age, 
which was the global age distribution trend during the 2009 pandemic. However, the 
real mortality rates may be far from these crude estimates since it is challenging to 
determine the impact of underlying co-morbidities on influenza-associated deaths. 
Emergence of the pH1N1/09 influenza is exclusively reviewed in (Medina & García-
Sastre 2011). 
2.3.6 Future	outbreaks	–	preparing	for	the	unknown	
The glycosylation profile of the pH1N1/09 is equal to the one of the temporarily distant 
pH1N1/18, which indicates that due to immune selection pressure in the human 
population the pH1N1/09 HA may acquire similar glycosylations as those that occurred 
during the past decades (Wei et al. 2010). The N-glycosylation status seems to be 
important for influenza A virus evolution and therefore detailed assessment of the post-
translational modifications may improve preparedness to upcoming outbreaks. Due to 
rapidly growing knowledge on the impact of glycosylations for influenza virulence and 
antigenicity, the question of N-linked glycosylation remains a hot topic in the influenza 
research field. However, the future of influenza A viruses is highly unpredictable since 
it is well known that various factors influence on the emergence of novel variants. An 
outbreak of a new human pandemic virus would require genetic reassortments between 
viruses of different zoonotic origin, receptor adaptation and acquirement of high 
transmissibility and virulence. The highly pathogenic avian viruses have been a 
potential health threat for the human population for decades but fortunately the 
                                                          
5 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5819a1.htm (accessed 21.3.2013) 
16 
 
adaptation of the viruses hasn’t been successful enough to enable human-to-human 
transmission. 
The chances are that a new reassortment event has already occurred in some isolated 
animal population and it is only a matter of time when the virus acquires the ability to 
cross the species barrier and spreads to the world via migrating birds, international 
animal transportation or other global routes. Animal and human surveillance 
programmes form an important part of the preparedness for novel influenza variants and 
are coordinated globally by the National Influenza Centres (NIC)6 of the Global 
Influenza Surveillance and Response System (GISRS)7 and the NIAID Centers of 
Excellence for Influenza Research and Surveillance (CEIRS)8. Surveillance of wild and 
domestic animals, especially avian species, forms an important part of preparedness for 
new animal outbreaks and helps to evaluate the potential risk of a new human disease 
(Fouchier et al. 2003, Peiris et al. 2012). Additionally, the most important method of 
preventing influenza transmission is by creating herd immunity with annually updated, 
heterosubtypic influenza vaccines. 
2.4 Immune	responses	to	influenza	virus	
2.4.1 Hemagglutinin	(HA)	−	the	main	immunogenic	protein	of	the	virion	
HA is the major envelope glycoprotein with a shape of trimeric rod at its C-terminus 
and a globular head structure at its N-terminus. It protrudes from the lipid envelope of 
the viral surface as a type I integral membrane protein, with its hydrophilic carboxy 
terminus within the lipid layer. The full functionality of HA requires post-translational 
glycosylations, palmitoylations and maturation cleavage of the precursor HA0 into two 
subunits, HA1 (globular head) and HA2 (stem) (Klenk et al. 1975). The globular head 
of a mature HA molecule is a trimer, derived from three HA1 monomers. Epitope 
mapping has revealed the type H1 HA globular head to possess the SA receptor 
−binding site surrounded by the five antigenic regions Ca1, Ca2, Sa, Sb and Cb, present 
in each HA monomer (Figure 5) (Caton et al. 1982). The antigenic sites are distributed 
over four conformational epitopes, of which sites Sa and Sb lay adjacent to the receptor-
binding pocket (Xu et al. 2010). The globular head trimer contains the main 
immunodominant regions and antigenic epitopes for induction of immune responses 
(Wiley & Wilson 1981), which makes HA the main target of nAbs (Han & Marasco 
                                                          
6 
http://www.who.int/influenza/gisrs_laboratory/national_influenza_centres/national_influenza_centres.pdf 
7 http://www.who.int/influenza/gisrs_laboratory/en/ 
8 http://www.niaid.nih.gov/labsandresources/resources/ceirs/Pages/centers.aspx 
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2011) that are induced by infection and vaccination. HA contains the major antigenic 
regions targeted by the current commercial influenza vaccines, which creates high 
selection pressure and drives rapid escape of the virus from the pre-existing nAbs 
(Webster et al. 1992). 
 
Figure	5.	 Structure	 of	 a	hemagglutinin	monomer.	Ribbon	 diagram	 of	 an	 influenza	 A	 (H1N1)	virus	with	the	sialic	acid	receptor-binding	site	surrounded	by	the	five	antigenic	sites.	Protein	Data	Bank	 ID:	 3LZG;	 image	 created	 with	 PyMol	 Molecular	 Graphics	 System,	 version	 1.1eval.	 Figure	modified	from	(Bouvier	&	Palese	2008).	
The other main biological function of the HA globular head is to recognise and bind to 
the neuraminic acid receptors on host epithelial cell surface that express SA α-2,6Gal or 
SA α-2,3Gal (Weis et al. 1988). The receptor specificity of influenza viruses is species- 
and subtype-specific, as discussed in Chapter 2.2.1. The SA receptor binding site is 
located in the shallow pocket of the HA globular head within a close proximity to the 
hypervariable antigenic regions and contains the highly conserved amino acids Tyr98, 
Trp153, His183, Gln190, Leu194 and Tyr195 (Wilson et al. 1981). The HA stem is a 
coiled coil structure of three α-helix HA2 monomers and has a fusion peptide cleavage 
site at its C-terminus. It has been proposed that the stem bears a highly conserved region 
that might be involved in cross-neutralisation of diverse viruses and may also block 
membrane fusion during virus entry (Okuno et al. 1993, Ekiert et al. 2009, Sui et al. 
2009).  
N-linked glycosylation is one of the most common post-translational protein 
modifications in mammalian cells that occur in approximately 50% of all proteins 
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(Apweiler et al. 1999). In general, early in the protein synthesis a high mannose core is 
added in the amide nitrogen of asparagine at the universal Asn-X-Ser/Thr (N-X-S/T) 
glycosylation sequon, where X can be any amino acid except proline (Bause 1983). The 
oligosaccharides become further trimmed during transport through ER and Golgi, 
acquiring variable sugar moieties. Post-translational modifications of glycan chains are 
organism-, tissue- and cell type-specific and often depend on secretory context, 
enzymatic exposure and protein structure (An & Cipollo 2011). Viruses utilise N-
glycosylation modifications to ensure correct folding, interactions, stability and 
functionality of their surface proteins HA and NA. Both the HA HA1 and the HA2 of 
seasonal H1N1 viruses pose a variable number of N-glycosylation sites in close 
proximity to the antigenic sites that can be potentially post-translationally modified.  
 
Figure	6.	Types	of	asparagine	(N)-linked	glycans.	The	possible	combinations	of	oligosaccharide	side	chains	that	can	occur	on	the	influenza	virus	surface	proteins	HA	and	NA.	Figure	modified	from	(Stanley	et	al.	2009).	
The oligosaccharide side chains found in influenza virus HA can be commonly divided 
into high-mannose type, complex type and hybrids of these two (Figure 6) (Stanley et 
al. 2009). Multiple outer branches and additional sugar residues characterize the 
complex type oligosaccharides, whereas the high-mannose type contains two to six 
extra mannose units attached into the pentasaccharide core. The complex N-linked 
oligosaccharides of HA have several glycoforms and may be neutral, sialylated and/or 
sulfated depending on the host cell (Yagi et al. 2012). Sulfation occurs in the 
medial/trans-Golgi and trans-Golgi network by specific sulfotransferases (Spiro & 
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Spiro 2000). This structural processing may be essential for the addition of terminal 
anionic groups after the SA residues have been removed by the viral NA. For more 
information on N-linked oligosaccharides, see a review by Kornfeld & Kornfeld (1985) 
and for discussion of the molecular basis of N-glycosylation of influenza HA and 
glycoproteins of other important human pathogens, see a review by Vigerust and 
Shepherd (2007). 
O-linked glycosylation is another common covalent modification of mammalian 
glycoproteins but has also been discovered from certain viral glycoproteins, such as the 
HIV-1 envelope glycoprotein (Env) (Bernstein et al. 1994). O-glycans are covalently α-
linked via an N-acetylgalactosamine (GalNAc) moiety to the -OH of serine (S) or 
threonine (T) by an O-glycosidic bond, can be sialylated and occur as highly complex 
branched structures. More information on the general structure and functions of O-
linked glycans can be retrieved from the reviews (Van Den Steen et al. 1998) and 
(Brockhausen et al. 2009). Herpes simplex virus type 1 glycoprotein C has numerous 
clustered O-linked glycans that seem to be part of the complex viral strategy but to have 
yet unspecified functions (Biller et al. 2000). Additional variable region 1 (V1)-
associated N- and O-linked glycosylations in the surface component of the simian 
immunodeficiency virus (SIV) Env protein were shown to alter the antigenicity of the 
virus, likely by masking its major neutralising epitope (Chackerian et al. 1997). The 
authors suggest that these changes in S and T residues within the V1 region of the viral 
variants contributed to immune escape from nAb recognition during progression from 
clinical latency to AIDS in macaques. The functional and structural roles of O-linked 
glycosylation are less known for influenza A. O-glycan associated Lewis X 
oligosaccharides have been found solely on the HA of embryonated egg –propagated 
viruses but not on the HA of MDCK cell-derived viruses (Yagi et al. 2012). 
2.4.2 Immunogenic	role	of	the	enzyme	neuraminidase	(NA)	
NA glycoprotein is a receptor-destroying sialidase enzyme and the second most 
abundant protein on the influenza virion surface. It is a mushroom-shaped, tetrameric 
type II integral membrane protein with its N-terminus (stem) towards the virion core 
and the bulky head outside of the virus particle. The NA head consists of four 
homotetramers of six β-sheets in a propeller formation and harbours five potential N-
glycosylation sites, four of which are known to be glycosylated (Varghese et al. 1983). 
The enzyme catalytic sites are located in the box-shaped head domain and are 
surrounded by the antigenic determinants (Colman et al. 1983). In a mouse study highly 
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purified NA was shown to elicit equal amounts of NA-specific antibodies compared to 
HA-specific antibodies elicited by purified HA (Johansson et al. 1989). However, the 
immunity induced by these two immunogenic proteins differed significantly − NA 
allowed influenza infection while the HA-specific immune responses were able to 
inhibit infection. It is now well known that NA antigen is capable of eliciting humoral 
immune responses in the host, although the infection-blocking nAbs have been shown 
to be mainly directed against HA. Constant mutations occur in the antigenic regions, 
thus affecting in the overall antigenic drift of the virus. 
NA has an important role in viral replication and in the release of mature virus particles 
from the infected cell (Palese & Compans 1976). With its enzymatic activity the 
receptor SAs, viruses and mucus are removed from the cell surface, which enables virus 
spread. An infected cell is simultaneously being protected from further recognition of 
new viruses and the formation of progeny virus aggregates is prevented on the cell 
surface (Palese et al. 1974). SA-containing oligosaccharides adjacent to the receptor 
binding site have been shown to have inhibitory effect on the hemagglutinating activity 
of the influenza A viruses by possible steric hindrance or filling of the receptor binding 
pocket, which confirms the important role of the NA in the removal of the SA moieties 
(Ohuchi et al. 1995). The functions of NA in the final stage of the infection are well 
recognised but its role in the earlier stages is less known. Studies on the human airway 
epithelial cells in vitro suggest that NA may contribute to the infection by facilitating 
the virus entry into the cell, most likely by removal of decoy receptors on mucin, cilia 
and cellular glykocalix (Matrosovich et al. 2004b). However, further studies are 
required to evaluate the possible additional roles of NA in other stages of viral invasion. 
2.4.3 The	nucleoprotein	(NP)	–	a	structural	protein	with	immunogenic	
properties	
The structural protein NP has its primary role in encapsidating the viral genome into 
RNPs and is therefore essential for transcription, replication and packaging processes. 
Additionally, it is known to function as an adapter between virus and host cell processes 
and to contribute to viral adaptation and pathogenicity [reviewed in (Portela & Digard 
2002)]. A substitution mutation D375N in the NP protein of a pH1N1/09 strain was 
shown to independently contribute to increased virulence and thus adaptation in mice, 
as compared to seven other identified mutations (Sakabe et al. 2011). In this study, this 
mutation was shown to be responsible for increased pathogenicity in mice along with 
four other mutations in PA and HA proteins. NP-375D is known to be highly conserved 
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among the avian, most classical swine viruses and most pandemic H1N1 viruses 
(Dawood et al. 2009, Garten et al. 2009, Smith et al. 2009), whereas seasonal strains 
consistently have V or G at this position. 
Additionally, NP is the third immunogenic protein of influenza A virion, capable of 
eliciting antibodies in the host organism. It has been shown that inter-subunit 
interactions between monomeric NPs and NP-NP interactions contribute to the 
antigenic structure of NP polymers and the formation of the N5D3 epitope (Prokudina 
et al. 2008). NP has been shown to elicit cellular T lymphocyte responses and humoral 
responses that both have a role in cross-protection against new viral serotypes in mice 
(LaMere et al. 2011). In this study, anti-NP IgG was shown to promote influenza 
clearance by mechanisms involving Fc receptors and CD8+ cells in mice. It was also 
capable of enhancing NP-specific CD8 T cell responses in B cell deficient mice. 
Additionally, all antiviral activity was lost when mice were vaccinated with an 
interferon antagonist protein NS1. Consequently, the authors suggest that the highly 
conserved NP antigens could provide additional heterosubtypic cross-protection for 
current influenza vaccines that are poorly effective against the constantly drifting 
external HA and NA antigens. 
2.4.4 Influenza	proteins	as	antagonist	of	the	innate	and	cellular	immune	
responses	
A mitochondrial protein PB1-F2 has been shown to have apoptotic characteristics and 
to be associated with cell-type specific enhancement of cell death (Chen et al. 2001). 
This protein is now known to be expressed at differing levels in individual cells, to be 
degraded rapidly in a proteasome-dependent manner and to be completely absent from 
some influenza virus isolates. PB1-F2 carries a short positively charged amphipathic α-
helix mitochondrial targeting sequence similar to other viral proteins close to its C-
terminus that is responsible for mitotoxicity (Gibbs et al. 2003). This protein is also 
known to have a role in enhancing inflammation during primary viral infection in mice 
and in increasing frequency and severity of secondary bacterial pneumonia (McAuley et 
al. 2007). This study suggests that PB1-F2 has an important role in lung pathology, 
especially observed during the pH1N1/18, but its mode of pro-inflammatory activity is 
to be further studied. According to the study, PB1-F2 clearly affects the virulence and 
facilitates secondary bacterial infections by a currently unclear mechanism. 
Evading immune recognition has been shown to be utilised by an influenza dsRNA 
inhibitory molecule NS1 that inhibits intracellular signalling and specifically type I 
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interferon (IFN) production in infected cells, including epithelial cells and DCs (López 
et al. 2003). This important virulence factor was shown to suppress DC maturation, 
migration and T cell stimulatory activity by modulating multiple cytokine genes in vitro 
(Fernandez-Sesma et al. 2006). The study suggests the NS1 to have an important dual 
role involving modulation of both innate and adaptive immune responses. The 
interferon antagonist mechanism of this protein is to inhibit RIG-I ubiquitination via a 
TRIM25 ligase (Gack et al. 2009). This suppresses RIG-I signal transduction, which 
thereby modulates antiviral immunity by inhibiting type I IFN production and thus 
gives a huge advantage for innate immune evasion. In a recent study the NS1 protein 
was shown to further suppress IFN response when expressed together with PB1-F2 
(Varga et al. 2011). It is probable that during future influenza virus research new 
virulence markers arise or novel properties are found for the currently known viral 
factors. However, the proteins presented here are known to be the main actors at 
inducing influenza-mediated innate and adaptive immune responses in the host 
organisms. 
2.4.5 Cellular	and	humoral	responses	to	influenza	
Adaptive immunity elicited by influenza virus infection in humans consists of antibody-
mediated and cell-mediated immune responses. The cellular responses against HA viral 
protein involve the effector T lymphocytes – CD4+ T helper cells and cytotoxic CD8+ 
T cells. Optimal T cell response consists of IFN-γ –secreting CD4+ cells and CD8+ 
cells that lyse virus-infected cells (Zinkernagel 1996) and anti-inflammatory cytokine 
IL-10-producing effector CD4+ and CD8+ T cells that have been shown to regulate the 
extent of pulmonary inflammation (Sun et al. 2009). Long-lasting virus-specific effector 
memory CD8+ T cells have been shown to proliferate and to migrate into lung airways 
after recovery from viral clearance, which promotes mucosal immunity (Hogan et al. 
2002) and can be activated against heterosubtypic challenge and response to secondary 
viral infection. Life-long HA-specific B cell memory seems to be operated either by 
antibody-secreting cells (ASC) or resting memory B cells (MBC). During a re-exposure 
to influenza antigens, cross-reactive helper T cells induce the production of B cells. 
Circulating MBCs affinity mature and differentiate into plasma cells that are able to 
produce protective nAbs, which gives them an ability to rapidly neutralise close variants 
that are introduced via subsequent vaccination or natural infection [vaccine-induced 
immunity is reviewed in (Dormitzer et al. 2011)]. Cellular immunity is essential for 
effective virus clearance and recovery (Graham & Braciale 1997) while nAbs seem to 
23 
 
provide the primary protection against re-infection (Murphy & Clements 1989, Skehel 
& Wiley 2000).  
2.5 Influenza	pathogenesis	in	the	human	host	
Influenza A viruses produce a characteristic respiratory disease in each of their host 
organisms. In birds the disease is mostly asymptomatic but occasionally systematic 
infection involving the central nervous system occurs and can lead to death. The 
symptoms of swine influenza resemble the symptoms of human infections, including 
nasal discharge and congestion, coughing, high fever, laboured breathing and 
conjunctivitis. In humans the acute disease additionally includes body aches, severe 
headache, chills and sore throat. In children nausea and vomiting are possible outcomes 
and occasionally the disease progresses into fatal primary (viral) or secondary 
(bacterial) pneumonia that are a major cause of severe morbidity and mortality 
following influenza infection in paediatric and geriatric patients, even in previously 
healthy individuals (Brundage 2006, Finelli et al. 2008). The viral and host 
pathogenicity factors that affect the disease severity are known to function in a complex 
manner and much remains to be uncovered about the impact of different factors on the 
clinical manifestation of this commonly self-limited illness. 
2.5.1 Viral	pathogenicity	factors	
The virulence of influenza A is a consequence of complex and multigenic co-operation 
of viral determinants [reviewed in (Medina & García-Sastre 2011)]. The major factors 
are the host tissue tropism, adaptations in receptor binding specificity (discussed in 
Chapter 2.3.4) and the sequence of the HA peptide cleavage site, in addition to the 
immunogenic proteins HA, NA and NP discussed in the previous chapters. The 
sequence of HA cleavage site is variable among low-pathogenic (H1, H2, H3) and high-
pathogenic (H5, H7) strains and functions as a major determinant of disease severity. 
Low-pathogenic strains have a single arginine amino acid at the cleavage site that is 
recognised by extracellular and human airway epithelium trypsin-like proteases present 
only in the respiratory mucosal and intestinal surfaces, whereas high-pathogenic viruses 
possess a multibasic cleavage site that is cleaved by intracellular proteases that can be 
found in multiple organs. This characteristic is believed to allow increased virulence 
and rapid spread of the H5N1 virus into the central nervous system and has been shown 
to cause severe neurological defects such as neuroinflammation and neurodegeneration 
in mice (Jang et al. 2009).  
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2.5.2 Host	pathogenicity	factors	
A variety of host factors that affect the disease outcome and the virulence of influenza 
virus have been determined by recent RNAi-based genome-wide screenings and are 
discussed in reviews by Medina & García-Sastre (2011) and Watanabe and colleagues 
(2010). In addition to various cellular markers that interfere with different stages of viral 
replication, obesity (CDC 2009, Webb et al. 2009), diabetes (Carcione et al. 2010, Jain 
et al. 2012), cardiovascular diseases (Hanshaoworakul et al. 2009), asthma (Jain et al. 
2012), pregnancy (Webb et al. 2009, Creanga et al. 2010, Louie et al. 2010, Jain et al. 
2012), chronic pulmonary disease (CDC 2009, Hanshaoworakul et al. 2009, Webb et al. 
2009), First Nations ethnicity (Canadian Aboriginals) (Zarychanski et al. 2010), 
indigenous origin (Australia and New Zealand) (Webb et al. 2009) and generally 
increased inflammatory responses have been shown to be considerable underlying risk 
factors of susceptibility for severe morbidity and mortality caused by seasonal and 
pandemic influenza A viruses.  
Generally during seasonal influenza A outbreaks the portion of the population requiring 
most hospitalisations consists of the youngest and the oldest age groups of the 
population. High susceptibility has been observed within the elderly over 65-years with 
chronic co-morbidities (Thompson et al. 2004, Li et al. 2009). The high risk has been 
postulated to be due to immunological senescence and generally weakened immune 
responses that can cause as high as 90% excess mortality rate in the hospitalised 
patients [reviewed in (Webster 2000)]. Naïve immune system and frequent contacts 
with other children have been shown to be the factors that promote the high frequency 
of influenza infections in infants and school-aged children (Wallinga et al. 2006, 
Mossong et al. 2008). However, during the pH1N1/09 the disease severity patterns were 
distinctly different from the previous outbreaks. Adults at 25−64-years of age were the 
group with increased disease severity, highest hospitalisation rates and most visits in the 
intensive care units (Steens et al. 2011). In a case study in the USA during this 
pandemic, almost half of the persons who required hospitalisation were younger than 18 
years old, while only 5% were senior patients of 65 years of age or older (Jain et al. 
2012). However, risk of death from the pH1N1/09 virus increased along with increasing 
age (Webb et al. 2009). A distinct pattern was observed as the one seen during the 
pH1N1/18 since the mortality was highest among the young population (Simonsen et al. 
1998).  
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The phenomenon known as cytokine storm involving high chemokine and cytokine 
levels, especially IL-15-dependent CD8+ cells, has been shown to have a critical role in 
acute pneumonia and influenza-induced lung injuries caused by an infection with highly 
pathogenic influenza viruses (Nakamura et al. 2010). Other host determinants of 
pathogenesis include the IFNγ-induced protein (IP10), monocyte chemoattractant 
protein 1 (MCP1), interleukins 6 (IL-6), 8 (IL-8), 10 (IL-10) (Sun et al. 2009) and 12 
(IL-12) and other pro-inflammatory cytokines/chemokines and cell death genes whose 
up-regulation were shown to correlate with sustained pathology and severe tissue 
damage in pH1N1/18 influenza infection (Cillóniz et al. 2009). An earlier study has 
implicated high pharyngeal viral load, cytokine storm and viral presence in the blood to 
be the factors correlating with fatality due to viral pneumonia caused by systemic H5N1 
influenza virus infection (De Jong et al. 2006). In addition to intense inflammatory 
responses, in this study mutations in the viral polymerase complex were found that were 
thought to indicate mammalian adaptation and virulence. Since the virus uses a complex 
network of cellular host functions during all steps of its life cycle, it is important to 
obtain detailed information on their significance on the viral replication. Improved 
knowledge on the impact of host factors and adaptive mutations on disease severity is 
an important tool for therapeutic improvements. 
Protection from live influenza challenge in the respiratory tract is known to occur by co-
operation of local nAbs, secretory IgA and serum subtype-specific anti-HA antibodies 
(Clements et al. 1986, Johnson et al. 1986). Immunoglobulins IgG, IgA, IgM and 
secretory IgA are involved in humoral protection against influenza infections and can 
also have neutralising activity (Couch & Kasel 1983). The neutralisation effect of anti-
HA monoclonal IgG antibodies were initially shown to be due to their ability to inhibit 
the transcriptase and to prevent primary transcription (Possee et al. 1982, Rigg et al. 
1989), while attachment, entry and uncoating of the virus was suggested to be 
successfully completed. In contrast to these results, more recent studies on H5N1 
influenza showed that the nAbs are targeted against the highly conserved epitope in the 
stem region that contains the fusion peptide and therefore the nAbs neutralise the 
infection by blocking membrane fusion (Sui et al. 2009). While nAbs seem to be 
responsible for inhibition of viral entry, anti-NA antibodies are thought to provide 
secondary protection against influenza infections by inhibiting the release of newly 
assembled virions. 
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Unusual severity was observed from pH1N1/09 influenza infection in previously 
healthy middle-aged individuals (Monsalvo et al. 2011). The authors report influenza-
induced disease severity to be due to immune complex-mediated disease involving pre-
existing cross-reactive but non-neutralising low-avidity antibodies, in addition to 
pulmonary immune complex-mediated complement activation. Influenza immunology 
is further complicated by the phenomenon of “original antigenic sin” (Davenport et al. 
1953, Francis 1953) that opposes the general Burnet’s rule of B cell engagement and the 
existence of which has been questioned during the past 60 years of influenza research. 
According to the original sin theory, upon an influenza re-infection with a novel strain 
protective antibodies are produced extensively against the original antigens of the 
primary virus, even at the expense of the novel antigens. As a result, significantly 
decreased protective immunity is raised against the newly introduced strain that does 
not provide sufficient protection from the new pathogen. Recent studies on this 
somewhat debated topic suggest that original antigenic sin may actually exist and 
possibly functions as a viral bypass strategy from the immune recognition (Kim et al. 
2009). 
2.5.3 Pre-existing	humoral	immunity	
Previous exposure to influenza viruses determines the level of pre-existing subtype-
specific and cross-reactive nAbs in an individual. The level and versatility of the cross-
reactive antibodies against different influenza A viruses is known to have an important 
role in protecting against new emerging viruses and correlates with the pandemic 
potential of the viruses in the overall human population. Cross-reactivity can be found 
among strains that contain antigenically similar regions in the HA globular head, in 
addition to the highly conserved main immunogenic regions in the HA stem region. 
Since the emergence of the pH1N1/09, the molecular mechanisms of nAb cross-
reactivity has been studied extensively due to the significant antigenic resemblance of 
pH1N1/09 to the previous pandemic strain pH1N1/18 (Figure 7).  
 
Recent studies have revealed neutralisation targets within the globular head domain of 
the HA that provide high cross-neutralisation activity among the pH1N1/18 and the 
pH1N1/09 strains (Manicassamy et al. 2010b). Cross-reactivity is based on the 
antigenic similarity between these pandemic strains, a finding that resulted from 
comparison of their sequences and N-glycosylation profiles. The seasonal H1N1 strains 
contain two highly conserved glycosylation sites at positions 129 and 163 within the 
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antigenic site Sa, whereas both pH1N1/18 and pH1N1/09 strains have non-glycosylated 
HA globular heads (Xu et al. 2010). Additionally, the amino acid identity between the 
HA globular head of the p/H1N1/18 and the p/H1N1/09 is as high as 80%, which is a 
common divergence among seasonal influenza viruses and provides resistance for 
antibody neutralisation, while the amino acid identity is only 58−67% between the 
seasonal and pandemic strains (Wei et al. 2010). Furthermore, the amino acid 
differences between pH1N1/18 and pH1N1/09 virus are localised mainly in the Ca 
region, while Sa, Sb and Cb epitopes show high level of conservation (Xu et al. 2010).  
 
Figure	 7.	 Comparison	 of	 antigenic	 differences	 in	 the	 HA	 of	 pH1N1/18,	 pH1N1/09	 and	 a	
recent	seasonal	H1N1	strain.	Surface	 top	view	of	a	trimeric	HA	showing	the	antigenic	sites	and	their	 differences	 among	 the	 A/South	 Carolina/1/18,	 A/California/04/09	 and	 a	 seasonal	 strain	A/Brisbane/59/07.	Blue	colour	corresponds	to	conserved	amino	acids,	whereas	red	colour	shows	differing	amino	acids	 from	pH1N1/18	HA.	Antigenic	sites	are	coloured	 in	 light	blue;	 the	close-up	shows	 antigenic	 site	 Sa	 with	 yellow	 residues	 responsible	 for	 mAb	 escape	 mutations.	 Figure	modified	from	(Manicassamy	et	al.	2010b).	
	
An IgG antibody 2D1 from a survivor of the pH1N1/18 influenza was shown to be 
directed against a conserved epitope at the immunodominant antigenic site Sa and to be 
able to neutralise both pH1N1/18 and pH1N1/09 viruses (Xu et al. 2010). This finding 
suggests the antigenic site Sa to have a major role in antigenicity of these pandemic 
strains. The level of cross-reactivity between pH1N1/18 and pH1N1/09 has been 
addressed in various recent studies. Exposure to one pandemic strain has been shown to 
protect against a challenge by the other strain and to lead to significantly reduced 
morbidity and/or mortality. Moreover, titres nearly equal to homologous neutralisation 
titres were obtained between pH1N1/18 and pH1N1/09, while immunization with 
contemporary seasonal strains showed no cross-neutralisation activity against neither of 
these strains (Manicassamy et al. 2010b, Medina et al. 2010, Wei et al. 2010). This 
phenomenon has also been demonstrated in human vaccination studies. Medina and 
colleagues confirmed that antisera from individuals immunised with the pH1N1/09 
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vaccine had high cross-protection against a pH1N1/18 virus, at close to homologous 
titres (Medina et al. 2010). On the contrary to the trend observed with the seasonal 
strains, during the 2009 pandemic individuals older than 65 years were the most 
protected age group of the population by having considerably high seroprevalence of 
cross-reactive antibodies against the pH1N1/09 virus, which indicates previous 
exposure to an antigenically similar pH1N1/18 virus and/or its post-pandemic variants 
that continued circulating in the human population (Hancock et al. 2009, Xu et al. 
2010).  
This observed high cross-protection between the pandemic strains has opened new 
insights into studying the molecular basis of H1N1 virus antigenicity and the 
immunomodulatory impact of additional glycosylations in the HA globular head in the 
non-glycosylated pH1N1/09 virus background. In a study from 2010 by Wei and 
colleagues (2010), two HA globular head glycosylation sites, 142 and 177, were 
introduced into the pandemic A/South Carolina/1/1918 and A/California/04/2009 
viruses by site-directed mutagenesis. These mutant viruses showed significantly 
increased resistance against neutralisation by the WT p/H1N1/18 or WT p/H1N1/09 
antisera when compared to their non-glycosylated counterparts. In the same study 
antisera from mice immunised with the glycosylation mutant p/H1N1/18 virus was able 
to neutralise both the WT p/H1N1/18 and the mutant p/H1N1/18 viruses, which 
indicates that immunisation with a virus with additional HA globular head 
glycosylations could provide protection against glycosylated seasonal variants that have 
undergone antigenic drift. 
2.6 Influenza	vaccine	design	
2.6.1 Reverse	genetics	methods	
Reverse genetics methods were first developed for influenza virus in the beginning of 
the 1990’s and have ever since provided invaluable information of the genetics and 
replication of the (−) RNA viruses (Luytjes et al. 1989, Enami et al. 1990). Reverse 
genetics provides tools for constructing recombinant virus particles from cloned cDNAs 
and thus allows to perform functional studies at the molecular level by mutagenesis of 
the viral genes [see introduction to reverse genetics in (Palese & Shaw 2007)]. Influenza 
A genome is segmented, which has complicated the reverse genetics methods compared 
to viruses with a single genomic RNA molecule. This means that the segments are 
cloned into separate plasmids and have to be all taken up by the host cell to allow the 
generation of infectious particles into the growth medium. A finding that expanded our 
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knowledge on utilisation of these techniques was that the replication of (−) ssRNA 
viruses in the cell requires the formation of RNP complexes in vitro from synthetic 
cDNA (Honda et al. 1987, Parvin et al. 1989) and transfection of functional RNPs into 
cells, unlike the transfection of (+) ssRNA that readily leads to formation of infectious 
viruses. In the first systems, the constructed RNA was transfected into eukaryotic cells 
along with the purified NP, polymerase proteins (PB1, PB2, PA) and a helper influenza 
virus as a source of the other proteins required for replication (Luytjes et al. 1989), 
followed by selection of the novel virus from the helper virus (Enami et al. 1990).  
A decade after the birth of reverse genetics, the methods had undergone huge 
improvements that allowed rescue of infectious viruses by a non-helper virus system 
(Fodor et al. 1999, Neumann et al. 1999). In these studies the genome segments were 
cloned between a truncated human RNA polymerase I promoter and the hepatitis delta 
virus (HDV) ribozyme in negative orientation and transfected into cells along with two 
helper plasmids expressing NP and the polymerase complex. Today the rescue of 
influenza viruses from cDNA can be done efficiently by eight-plasmid systems that 
utilise an ambisense (bidirectional) plasmid for synthesis of mRNA and vRNA from the 
same template (Hoffmann et al. 2000a, Hoffmann et al. 2000b). In this method the 
sequences are cloned in positive-sense orientation between the human pol-I promoter 
and mouse terminator and the pol-I transcription unit is flanked by the cytomegalovirus 
(CMV) pol-II promoter and a polyadenylation site. This simplified technique replaced 
the previous laborious systems and allowed efficient recovery of recombinant and 
reassortant influenza A viruses without additional plasmids. Human embryonic 
kidney/Madin-Darby canine kidney cell (293T/MDCK) co-culture has turned out to be 
the most efficient for influenza rescue [reviewed in (Neumann & Kawaoka 2004)], 
although African green monkey (Vero) cells (Fodor et al. 1999) and 293T cells alone 
(Neumann et al. 1999) propagate influenza viruses. 
The drawback of the widely used systems that utilise RNA polymerase I promoter is 
that they only allow stringent, host-specific transcription that requires constructing a 
vector for each target cell type. In 2007 a novel minigenome method was developed that 
involves transcription of vRNA under the control of a T7 RNA polymerase (simian 
virus 40) promoter and allows cell type-independent transcription of influenza genes (de 
Wit et al. 2007). The vRNA was cloned into a unidirectional vector in antisense 
orientation between the T7 RNA polymerase in the 5’ end and a HDV genomic 
ribozyme and a T7 RNA polymerase terminator in the 3’ end. Although in this assay 
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gene expression was successfully enhanced by NLSs, the rescue efficiency was lower 
than for the RNA polymerase I dependent systems, which may be improved by 
developing a bidirectional system in the future. 
By generating mutations into the coding or non-coding regions of the viral genome, the 
role of different proteins or RNA domains in the replication cycle or pathogenicity can 
be studied. Reverse genetics has allowed virus production for biotechnology 
applications such as protein expression vectors, live attenuated vaccines, gene therapy 
and immunotherapy to deliver genes into specific target cells. The biomedical 
applications of reverse genetics techniques are exclusively reviewed in (Palese et al. 
1996, García-Sastre 1998). Viral-like particles (VLPs) are empty particles that 
structurally resemble virions but do not carry genetic material and are thus non-
infectious and safe. They can be engineered by reverse genetics methods to express 
various viral surface proteins and their assembly requires the expression of envelope of 
capsid proteins. VLPs can be produced in various mammalian, insect, yeast and plant 
cells and can be used for comprehensive antigenicity or mutagenesis studies of 
influenza viruses. There have been attempts to integrate VLPs into vaccine production 
by engineering highly immunogenic particles with HA and NA surface glycoproteins 
(discussed in Chapter 2.6.3). 
Reverse genetics has also enabled the rescue of the “extinct” pH1N1/18 virus from 
plasmid DNA, which has allowed extensive evaluation of the virulence and antigenicity 
of this highly virulent strain. Genomic RNA of the pH1N1/18 was initially recovered 
from formalin-fixed lung tissue of an Alaskan influenza victim that had died from the 
1918 Spanish flu (Taubenberger et al. 1997, Reid et al. 1999). This finding opened 
doors to complete analysis of the antigenicity and exceptional virulence of this virus. 
The virus was first reconstructed in 2005 from eight DNA plasmids (Tumpey et al. 
2005) with the available knowledge on the pH1N1/18 virus coding sequences of the 
eight genome segments (Taubenberger et al. 1997, Reid et al. 1999, Reid et al. 2000, 
Basler et al. 2001, Reid et al. 2002, Reid et al. 2004, Taubenberger et al. 2005). The 
1918 VLPs were created by reverse genetics methods described before (Fodor et al. 
1999, Basler et al. 2001) with the 5’ and 3’ non-coding regions from a closely related 
seasonal H1N1 strain (A/WSN/33).  
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2.6.2 Current	influenza	vaccines	and	their	limitations	
Since early 1940’s, virus propagation in embryonated chicken eggs has remained the 
gold-standard method for influenza vaccine production. The present vaccine 
applications recommended by WHO9 include intramuscularly administered inactivated 
vaccines. The seasonal trivalent inactivated vaccines (TIV) contain three selected strains 
− one influenza B strain and two influenza A strains − that had been the main viruses 
circulating in the human population during the previous season. The circulating 
seasonal strains are reviewed in February in the Northern Hemisphere, whereas in the 
Southern Hemisphere the review is carried out in September to predict which strains are 
likely to circulate in the population and cause human illness in the following winter. 
These strains are chosen for the next vaccine composition to ensure as good cross match 
as possible. In the absence of antigenic drift the pre-existing nAbs are likely to protect 
from the new circulating viruses and no alterations in the vaccine composition are 
required. The vaccine production circle is reviewed in (Gerdil 2003).  
Influenza A viruses are known to elicit long-lasting and strong mucosal and systemic 
immune responses in their host and therefore engineering of live attenuated recombinant 
virus vaccines (LAIV) by reverse genetics methods provides an appealing approach for 
vaccine applications. These viruses could potentially elicit longer-lasting, more specific 
CD8+ T cell responses in humans than the killed viruses used in the conventional 
inactivated vaccines. However, the recombinant approaches require further optimisation 
before entering the commercial markets. In order to design safe but highly 
immunogenic attenuated vaccines, the virus has to be non-pathogenic in all hosts and its 
phenotype has to be stabilised by non-revertible mutations. The first attempt to make an 
attenuated influenza virus by reverse genetics methods was by mutating the promoter 
region of the NA protein segment of a chimeric influenza A/B virus (Muster et al. 
1991). Attenuated viruses can also be made by introducing insertions, deletions or 
multiple mutations within the coding regions of the genes to produce a virus that 
successfully retains its attenuated temperature-sensitive phenotype (att and ts) during 
replication in vivo. Temperature-sensitive live attenuated influenza viruses have been 
made by introducing sequential missense mutations in the PB2 gene (Subbarao et al. 
1995). 
In addition to reverse genetics techniques, LAIVs can be produced by selecting the att 
mutations in one or more genes other than in the antigenic HA and NA. The att genes 
                                                          
9 http://www.who.int/influenza/vaccines/virus/en/ 
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are then transferred by genetic reassortment from the donor virus into a natural seasonal 
or pandemic influenza variant that carries the WT HA and NA to create a vaccine 
candidate. Studies on LAIVs that are cold-adapted at 25˚C, and whose growth is thus 
limited to the nasal passages, were initially started as early as in the 1960’s 
(Smorodintsev 1962, Maassab 1967). A trivalent intranasal influenza vaccine FluMist™ 
was developed as an alternative for conventional inactivated TIV vaccines and entered 
commercial markets in the USA in 2003 (Mossad 2003). The cold-adapted FluMist™ 
vaccine strain consists of HA and NA from currently circulating WT strains and PB1, 
PB2, PA, NP, M and NS gene segments of A/Ann Arbor/6/60 master donor virus (6:2 
reassortant) that confer ts and att phenotype by multiple amino acid residues in multiple 
genetic loci (Jin et al. 2003). The vaccine is administered as a nasal spray to induce 
mucosal immunity and has been shown to be immunogenic, effective and safe in 
humans including children (Belshe et al. 1998), adults (Nichol et al. 1999) and seniors > 
65 years of age (Jackson et al. 1999). However, more recent studies have shown low 
effectivity in adults (Belshe et al. 2008, Block et al. 2008) and currently this vaccine is 
only approved for use in persons aged 2 to 49 years10. 
Recent studies have shown FluMist™ to promote resistance to both seasonal circulating 
strains and pH1N1/09 swine-origin virus via common cross-protective T cell epitopes 
(Sun et al. 2011). Additionally, in mice immunised with this vaccine the IFN-γ 
responses were completely suppressed, which was shown to significantly decrease the 
susceptibility to secondary bacterial infection. They are a common cause of severe 
morbidity and mortality following influenza infection (Brundage 2006, Finelli et al. 
2008), which underlines the importance of this finding for the knowledge on influenza-
bacterial interactions during epidemics and pandemics. A cold-adapted live virus 
challenge is proposed to induce long-lived CD4 and CD8 T cell −mediated immunity in 
mice and to target common epitopes that are conserved between heterosubtypic 
influenza viruses (Powell et al. 2007). The authors reported very low-dose priming with 
live cold-adapted virus to lead to early viral clearance, greatly improved survival after 
lethal virus challenge and strong heterosubtypic protection for > 70 days. This strategy 
presents a potential emergency prophylactic measure during a lethal influenza pandemic 
in case the production of TIVs is delayed. 
The production of seasonal TIV vaccines follows a slow (6 months) annual process and 
has to take into account the accurate timing and production capacity to ensure the 
                                                          
10 http://www.medimmune.com/pdf/products/flumist_pi.pdf 
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availability of new updated vaccines prior to the beginning of each influenza season. 
Since the viruses are currently propagated in the allantoic cavity of slowly reproducible 
embryonated hen eggs, the availability of eggs determines the production efficiency. 
Although current egg production meets the needs, it is likely to become the limiting 
factor during influenza pandemics, which highlights the urgent need for alternative 
rapid production systems. It is also important to note that if a novel avian pandemic 
strain crosses the avian-human species barrier, the egg production becomes a serious 
problem. The other driving forces towards new, rapid methods is the fact that the widely 
used TIVs are relatively poor antigens in the elderly over 65 years of age, which is the 
fastest growing segment of the population, and that they are not suitable for egg-allergic 
individuals. The limitations of the vaccine production circle are reviewed in (Gerdil 
2003). 
The level of cross-protection induced by current subunit or split-influenza vaccines is 
dependent on broadly neutralising nAbs directed against HA and NA (Palese 2006). 
Different chemical and physical methods can be used to inactivate the influenza vaccine 
viruses, the most common being formaldehyde-inactivation. The impact of γ-irradiation, 
formalin- and UV-inactivation protocols on the cross-protective immunity has been 
compared with the commercial TIV vaccine. It was shown that only γ-irradiation of all 
these methods was able to conserve both homologous and heterosubtypic protection and 
lead to cytotoxic T cell responses that most likely are a key to cross-protective and long-
lasting immunity (Furuya et al. 2010). The current vaccines are only effective against 
antigenically similar, non-drifted strains and therefore have to be updated and 
administered each year, which involves big economical investments and annual 
vaccination programmes for the risk groups such as children, elderly and the health care 
workers. The major drawback of cold-adapted live viruses seems to be their 
significantly weaker immunogenicity measured by serum antibody levels, compared to 
their WT parental viruses with similar surface antigens (Tannock et al. 1984). 
Additionally, these vaccines still need to be administered annually to overcome the pre-
existing antibodies and therefore they do not provide a solution to the great demand for 
broadly protecting influenza vaccines.  
2.6.3 Novel	vaccine	approaches	
There have been numerous attempts to apply novel broadly effective and convenient 
approaches and cell lines to the vaccine field. The new technologies include the use of 
mammalian cell cultures, adjuvant vaccines, recombinant DNA vaccines, VLPs and 
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HA-based vaccines made in insect, yeast or plant cells, universal vaccines based on 
conserved proteins and antigens such as the HA stem, modified live viruses and 
prophylactic vaccines that elicit T cell responses. The primary immunogenic target of 
influenza vaccines is the variable antigen HA that constantly evolves so that current 
vaccines may not be effective against novel pandemic of highly virulent viruses. The 
influenza M2 ion channel protein and the HA stem domains provide potential conserved 
vaccine targets to improve the level of cross-protection against different subtypes and 
drifted variants. An excellent summary of new technologies for new influenza vaccines 
can be found in reviews (Chen et al. 2011, Kang et al. 2011, Shaw 2012). 
MDCKs are the standard cell line for influenza propagation for research and diagnostic 
applications but could also provide an alternative platform for large-scale vaccine 
production. The efficiency of virus replication in MDCK cells was shown to be better 
than in Vero cells, whereas the ratio of genome copies versus infectious units was better 
in Vero cells for cold-adapted and WT influenza A viruses (Youil et al. 2004). The 
immunogenicity and tolerability of an MDCK-produced inactivated HA subunit vaccine 
was shown to be equal to an egg-produced HA subunit vaccine (Palache et al. 1997). 
This was the first study in humans with a bivalent vaccine containing the HA antigen of 
an influenza A and an influenza B seasonal strain. A phase III vaccine study in adults 
showed a novel cell culture −derived seasonal trivalent influenza vaccine (CCIV) to be 
comparable to a TIV vaccine in its immunogenicity, efficacy, safety and reactogenicity 
(Szymczakiewicz-Multanowska et al. 2009). In a recent phase II/III randomised vaccine 
study these properties of a CCIV (Optaflu®, Novartis) were shown to be comparable to 
an egg-derived subunit TIV vaccine in a paediatric population (Vesikari et al. 2012). 
Both of the studied CCIV vaccines contained purified NA and HA antigens from two 
current seasonal influenza A and one influenza B strains. The results suggest that 
mammalian cell-based systems could provide a production platform for egg-protein 
free, non-allergenic HA subunit vaccines with better antigenic match to WT human-
derived viruses compared to the avian-derived vaccines. Other advances include 
improved controllability of contamination for cell-culture systems, in addition to 
improved vaccine production yields. 
Consistent results of immunogenicity were obtained with Nicotiana benthamiana plant 
–derived recombinant HA from two H5N1 strains that successfully elicited 
hemagglutination inhibition and nAb production in mice (Shoji et al. 2009). Protein 
Sciences produces trivalent recombinant influenza HA protein under the name of 
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FluBlok® that is expressed in Spodoptera frugiperda (Sf9) insect cells infected with a 
baculovirus vector (Cox & Karl Anderson 2007, Cox et al. 2008). This expression 
system has enabled the production of a highly pure vaccine free of egg-proteins, 
preservatives, endotoxins, adjuvants and antibiotics that contains three times more 
antigenic HA than TIVs and has been proved to elicit long-lasting and strong immunity 
against drifted influenza variants (Cox & Hollister 2009). FluBlok® has finished phase 
III studies and is currently waiting for final approval from the USFDA (Shaw 2012). 
Glycoprotein-based vaccines and therapeutics forms an emerging field in the current 
drug market and efforts have been made to evaluate the possible use of highly 
immunogenic HA or NA proteins that would elicit broadly neutralising nAbs capable of 
efficiently blocking the entry to airway epithelium and eliminating the novel drifted 
influenza virus variants and viruses from various subgroups over an extended period of 
time. The extremely high reproducibility of E. coli cells makes it an interesting platform 
for recombinant HA production on a large scale. The HA proteins produced in these 
bacteria do not contain glycans and could thus in theory be more immunogenic. 
Properly folded, trimeric globular HA2 peptides from E. coli were shown to elicit a 
potential nAb response against the pH1N1/09 in ferrets (Khurana et al. 2010). However, 
the proteins secreted from E. coli form insoluble, misfolded inclusion bodies that have 
to be solubilised with detergents and purified by dialysis in addition to monitoring the 
level of residual endotoxins (Marston 1986).  
Due to obstacles encountered with HA production in prokaryotic cells, yeast cells have 
been studied as a platform for fast and cost-efficient vaccine production. They have 
glycosylation pathways resembling the eukaryotic pathways and thus are an appealing 
method for large-scale vaccine production. Yeast Pichia pastoris −expressed 
recombinant H1N1 HA has been recently shown to elicit nAb responses in vivo 
(Athmaram et al. 2011). In this study successful HA trimers were produced in yeast that 
were capable of eliciting functional HA-specific antibodies in mouse and rabbit 
immunisations, measured by standard hemagglutination inhibition (HI) assays. The 
mice and rabbit antisera also lead to significant neutralisation of a pH1N1/09 infection 
in vitro, measured by plaque reduction tests. HA was produced with an excellent ratio 
compared to host proteins, which makes the processing of the recombinant product easy 
and economical on a large scale. Based on these characteristics, P. pastoris is  an  
appealing vaccine production platform that warrants further evaluation. 
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The possibility of using insect cells as a production platform has been evaluated in 
various studies for the production of VLPs and recombinant DNA vaccines. VLPs 
produced in Sf9 cells infected with baculovirus vectors containing an expression 
cassette with genes of HA, NA and M1 from an H3N2 isolate have been shown to elicit 
broader immune responses in mice and ferrets, compared to whole inactivated influenza 
virions and recombinant HA (Bright et al. 2007). The same expression system has also 
been utilised by Novavax in means of creating particles that resemble a seasonal H9N2 
influenza virion in their size and morphology (Pushko et al. 2005). These particles had 
preserved functional HA and NA properties and the capability of eliciting serum 
antibodies that inhibited virus replication following mouse challenge. An interesting 
advantage of VLPs is that they seem to be recognised by the particle-recognising 
mechanism of DCs, which has been shown to lead to virus uptake and activation of 
these cells (Song et al. 2010). In this in vitro DC/T cell co-culture system DCs in turn 
stimulated CD8+ T cells via antigen presentation, which suggests that VLPs share 
immunological advantages with live virus vaccines but with an improved safety profile. 
VLPs could potentially be more immunogenic than the HA alone, due their resemblance 
of complete influenza virions.  
Design of chimeric VLPs containing proteins from different influenza strains could 
potentially serve as a mechanism for creating vaccines capable of inducing broader 
immune responses (Pushko et al. 2005). The authors highlight the fact that purification 
of the VLPs from the recombinant baculoviruses possesses a challenge to be overcome 
prior to proceeding into commercial applications. A N. benthamiana plant-derived 
H5N1 influenza vaccine was developed that involves transient expression of H5 HA on 
the VLP surface by an Agrobacterium expression cassette (Landry et al. 2010). This 
vaccine has been shown to induce cross-reactive nAbs in in vitro neutralisation studies 
and in a preclinical ferret study and to be well tolerated and immunogenic in phase I 
clinical studies. The authors describe the first administration of a plant-derived VLP 
vaccine into humans with minor adverse effects and no observed hypersensitivity 
reactions to plant N-glycans. With the described system VLP vaccines can be produced 
within a month from sequencing of a novel pandemic strain, which is a vast advantage 
compared to manufacture of conventional egg-based vaccines. 
The HA globular head is constantly mutating, which complicates the design of broadly 
neutralising universal influenza vaccines. With response to that, vaccine candidates 
whose immunogenic focus is on conserved regions of ion channel protein M2 and HA 
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stem domains have been developed [reviewed in (Kang et al. 2011)]. Influenza A 
viruses are non-integrating and non-oncogenic viruses, which makes them potentially 
safe vectors. However, the pre-existing immunity against influenza viruses may possess 
a problem for use of influenza virus vectors in humans but could be circumvented by 
the use of antigenically different virus strains. Influenza viruses have been engineered 
by insertion of foreign epitopes into the HA antigenic sites and expression of 
polyproteins in order to create recombinant vectors for gene delivery. Chimeric 
influenza viruses have been created that express foreign epitopes and therefore induce 
humoral immune responses against the foreign pathogen or antigen. The addition of an 
epitope from H2 or H3 HA into the HA antigenic site B of an H1 virus created a 
chimeric virus capable of eliciting nAbs against both H3 and H1 subtype viruses (Li et 
al. 1992). The methods described present a very interesting approach for broadening the 
humoral cross-protection of influenza virus vaccines within the human population. 
Applications of influenza viruses as vectors are reviewed in (Garcia-Sastre & Palese 
1995). 
2.6.4 Prophylactic	treatment	of	influenza-related	illness	
The most effective strategy for prevention of influenza-related illness is by live or 
inactivated influenza virus vaccines. However, during a novel influenza pandemic the 
conventional vaccine production will most likely be severely delayed, which is why 
prophylactic drugs may come in handy in means of pandemic preparedness. Two types 
of antiviral drugs have entered the commercial markets: adamantanes and newer 
neuraminidase inhibitors zanamivir (Relenza; GlaxoSmithKline) and oseltamivir 
(Tamiflu; Roche). While adamantanes interfere with intracellular viral uncoating by 
inhibiting viral ion channel protein M2, neuraminidase inhibitors block the budding of 
mature influenza virions from the host cell surface. Licensed neuraminidase inhibitors 
have been shown to shorten influenza-related symptoms by one day when administered 
within 48h post-exposure in an initial study in healthy adults (Hayden et al. 1997) and 
in a paediatric population (Shun-Shin et al. 2009). For more information on 
neuraminidase inhibitors for influenza, see a review (Moscona 2005). In a recent study 
it was shown that a synthetic FLU-v vaccine containing conserved immunogenic 
regions of M1, M2, NPA and NPB was able to elicit IFN-γ responses in a randomised, 
double-blind, placebo-controlled phase I trial (Pleguezuelos et al. 2012). This approach 
is uncommon amongst influenza vaccines, since nAb responses were absent and anti-
viral effect was rather mediated by cellular mechanisms. This therapeutical agent could 
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offer a prophylactic approach to be used in line with novel HA/NA-based seasonal 
vaccines to control the influenza-related illness.  
2.6.5 Future	challenges	
A common goal is to establish production of vaccines carrying HA proteins that occupy 
uniform mammalian-like glycans and are highly immunogenic and non-allergenic to 
humans. The glycosylation pathways are likely to depend on the enzymes naturally 
present in each host-cell type (Yagi et al. 2012), which underlines the importance of 
validating the glycosylation profile of novel virus or subunit vaccine candidates to 
ensure their antigenicity, efficiency and safety. A recent study addressed the question of 
N-glycosylation profiles of a H3N2 virus isolate in embryonated eggs and MDCK cells 
by high performance liquid chromatography (HPLC) mapping (Yagi et al. 2012). The 
HA of viruses propagated in MDCK cells showed common trend of galabiose 
structures, whereas these structures were absent in viruses from embryonated eggs. In 
contrast, the O-linked oligosaccharides were absent in the viruses from MDCKs but 
present in the viruses propagated in embryonated eggs. The HA of viruses grown in 
MDCKs exhibited considerably more (10.2%) high-mannose type sugars than viruses 
from embryonated eggs (2.3%). In both virus groups the proportion of neutral 
oligosaccharides was 90% and 10% of the anionic oligosaccharides, the latter of which 
were sulfated but non-sialylated. A recent mass-spectrometry –based glycoform study 
showed an influenza B strain to contain high-mannose hybrid complex glycans with or 
without sulfation (An & Cipollo 2011). 
Vero cells are known to predominantly express α-2,3 galactose-linked SAs (Govorkova 
et al. 1996) which may constitute a major problem due to the variable viral N-
glycosylation profile of the produced viruses compared to the current egg-propagated 
viruses. H3N2 isolates obtained from Vero cells have also been shown to lack the 
ability to hemagglutinate chicken RBCs and to grow in chicken eggs, most probably 
due to their altered glycosylation profile that contains an elevated share of high-
mannose type oligosaccharides compared to MDCK cells (Romanova et al. 2003). In a 
recent study the glycoform composition of recombinant HAs produced in Sf9 insect 
cells and N. benthamiana plant cells was determined (Zhang et al. 2012). All 
glycosylation sites of the recombinant HAs produced in plants were shown to constantly 
contain high-mannose type glycans. In contrast, the HAs from insect cells showed high-
mannose type glycosylation mixed with the complex type glycans. Glycosylation 
pathways of a yeast P. pastoris have been successfully modified by genetic engineering 
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methods to mimic human and other mammalian cell N-glycosylation patterns 
(Bretthauer 2003, Choi et al. 2003, Hamilton et al. 2003, Gerngross 2004), which has 
opened new possibilities into glycoprotein production in yeast cells that challenge 
mammalian cell platforms. 
With a mass-spectrometry −based glycoform approach allergenic glycans, such as those 
containing fucosyl or xylosyl substitutions, of new vaccine candidates can be detected 
and the impact of new cell lines on the glycosylation profile can be evaluated (An & 
Cipollo 2011). A drawback of subunit vaccines can be their inability to elicit broadly 
neutralising immune responses directed against multiple immunogenic regions if only 
either HA stem or globular head is used for vaccine composition. Other factors to be 
considered are the stability, reproducibility and safe administration (minimal adverse 
effects) of the new vaccine candidates. The new vaccines should be cost-effective, 
easily manufactured in relatively short time-scale and their shelf life should be long 
enough to enable their sufficiency for the next few years to be able to cut out the costly 
annual vaccination programmes. There is a strong urge to design universal vaccines that 
would protect against multiple influenza A and B strains, be active at the respiratory 
mucosal surfaces and to cover various subtypes by eliciting broad, long-lasting (5−8 
years) humoral immune response in the vaccinated individuals (Couch & Kasel 1983). 
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3 Research	aims	&	hypothesis	
The research section of this thesis concentrates on assessment of the molecular role of 
HA glycosylations on the induction of humoral immune responses. Recent reverse 
genetics and site-directed mutagenesis –based studies have revealed important clues 
about the significance of these post-translational modifications on the virus antigenicity, 
immunogenicity, receptor binding affinity and specificity and immune escape from the 
host immune machinery. During the past decades the amino acid residues 71, 142, 144, 
172, 177 and 179 within the Sa antigenic site have acquired N-linked oligosaccharides 
within close proximity to the receptor-binding pocket of H1N1 HA (Figure 13). Based 
on the fact that these glycosylations occurred spontaneously in the nature, we were 
interested in assessing the impact of each single glycosylation on the breadth of the 
induced immune response and their possible role in masking of the antigenic site Sa. 
This thesis also aims at determining the level of cross-reactive antibodies elicited 
against the seasonally occurring H1N1 strains that have undergone antigenic drift, 
which would allow us to establish novel antigenic regions in the HA molecule that 
modulate H1N1 virus antigenicity. 
 
The level of cross-reactivity of mice and ferret sera induced by an infection with the 
recombinant wild type (rWT) A/Netherlands/602/09 (Neth/09) virus glycosylated at site 
144 (Neth/09-HA144) is evaluated against 14 natural seasonal H1N1 strains spanning 
years 1930−2009. With respect to previous studies (Medina et al. accepted), the 
Neth/09-HA144 is expected to elicit broad cross-reactivity against multiple natural 
seasonal H1N1 strains due to masking of Sa site. If this is true, it might suggest that this 
recombinant virus elicits polyclonal antibodies against other antigenic regions of HA 
that are likely to be outside of the antigenic site Sa. This project also aims at evaluating 
whether an infection with the Neth/09 virus containing additional HA glycosylations is 
able to induce broad polyclonal response in mice and ferrets. We aimed at engineering 
mutant viruses with single additional HA glycosylations at sites 71, 142, 172, 177 and 
179, reflecting their temporal appearance in previous seasonal H1N1 viruses. It was 
speculated that some of the monoglycosylated Neth/09 viruses might exhibit broad 
polyclonal response against the naturally occurring H1N1 strains and the previously 
produced polyglycosylated Neth/09 recombinants, while some of the glycosylations 
might narrow the humoral response due to the diminished antigenicity of these viruses, 
induced by possible steric hindrance or altered accessibility of the antigenic site. 
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4 Materials	&	methods	
4.1 Natural	H1N1	virus	sequences	&	alignment	
The HA sequences of all the H1N1 human viruses were downloaded from the Influenza 
Research Database11, aligned with ClustalW12 (Thompson et al. 1994) and edited 
manually using BioEdit Sequence Alignment Editor software13 (Hall 1999). The 
sequences containing representative glycosylation patterns for each year were selected 
for the alignment, whereas missing years correspond to lack of an isolate sequence for 
that year or unclear prototype sequence due to few sequences available. N-glycosylation 
sites were predicted based on the general amino acid motif N-X-S/T. Influenza 
Research Database accession numbers of the HA proteins in temporal order from 1918 
to 2012: AF117241, CY010788, NC_002017, CY009324, CY020445, CY013271, HQ008263, 
CY020285, CY021709, CY009596, U02085, CY019947, CY019971, CY009332, CY022093, 
AB043482, CY077748, CY077725, CY008988, CY010372, CY011296, CY021909, CY020181, 
CY021029, CY010364, CY020437, CY021725, Z54286, DQ508873, L33485, L19023, CY036943, 
L20111, CY033655, CY033614, CY017011, DQ415317, AF386775, CY031336, CY025026, CY010332, 
CY006675, CY019883, CY007467, CY016675, CY027875, CY058487, CY040114, CY050198, 
CY039527, CY060454, JN790366 and CY110745. 
4.2 Viruses,	cells	&	animals	
Table	 2.	 Influenza	 A	 viruses	 and	 mammalian	 cells	 that	 were	 used	 for	 this	 project.	 The	recombinant	pandemic	A/Netherlands/602/09	 strain	was	used	 as	 a	parent	 strain	 for	 all	 the	HA	glycosylation	mutant	viruses.	The	respective	1−4	additional	glycosylation	sites	of	each	mutant	virus	are	indicated	in	bold.	
Natural H1N1 isolates 
Glycosylation mutant 
viruses 
Mammalian cells 
A/Swine/Iowa/30 Parent strain: 
Virus propagation: 
A/PR/8/34 recombinant WT 
A/Netherlands/602/09 (rWT) A/Weiss/43 Madin-Darby canine kidney 
(MDCK) cells A/FLW/52 Recombinant mutant 
viruses: A/Denver/57 
Virus rescue: 
A/USSR/92/77 Neth/09-HA142 
A/USSR/79 Neth/09-HA144 Human embryonic kidney  
( 293T) cells A/Finland/13/80 Neth/09-HA172 
A/Houston/84 Neth/09-HA177 
Animal models 
A/Texas/36/91 Neth/09-HA179 
A/New Caledonia/20/99 Neth/09-HA71-142 7 to 9-weeks-old C57BL/6 female 
mice A/Brisbane/59/07 Neth/09-HA144-172 
A/California/07/09 Neth/09-HA71-142-177 8 to 12-months-old male Fitch 
ferrets A/Netherlands/602/09 Neth/09-HA71-142-172-177 
                                                          
11 http://www.fludb.org/brc/home.do?decorator=influenza (accessed 24.-25.4.2012) 
12 version 1.4. 
13 version 7.1.3.0 
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MDCK cells were used for all virus propagation (Table 2) and maintained in DMEM 
(#SH30081.FS / high glucose, Thermo Scientific) with 15% fetal bovine serum (FBS) 
and 2 μg/ml penicillin streptomycin at 37˚C in humidified atmosphere with 5% CO2. 
One of the available serum-free viral growth mediums (VGM) − Optimem® (#31985-
047, Gibco® Life Technologies), DME/F-12 (#SH30004.03, HyClone®, Thermo 
Scientific) with supplementary NaHCO3 and dextran or 1X MEM (#BW12-684F, 10X 
EMEM BioWhittaker®, Lonza) with supplementary penicillin/streptomycin, 0.21% 
bovine albumin, 0.12% NaHCO3 and 1% HEPES − was used for viral infections with 
supplementary 1 μg/ml of TPCK trypsin to allow mature virus particle budding from the 
infected cells. Cell culture growth was monitored daily by using an Olympus CKX41 
inverted microscope at 20 x magnification. All viruses (Table 2) had been previously 
produced by the Medina laboratory but were propagated and titrated during this project.	
The HA1 domains of the natural seasonal H1N1 isolates were sequenced (Macrogen, 
USA) to exclude the possibility of any additional mutations during passages in MDCKs. 
Sera collected from mice or ferrets (Table 2) were used for all serological assays. All 
animal research was conducted under the guidance of the Centers for Disease Control 
and Prevention's (CDC) IACUC in an Association for Assessment and Accreditation of 
Laboratory Animal Care International-accredited animal facility at Mount Sinai School 
of Medicine (MSSM) in New York, USA. 
4.3 Site-directed	mutagenesis	
Table	 3.	 Primers	 used	 for	 site-directed	 mutagenesis.	 The	 universal	 primers	 were	 used	 for	producing	 the	 ambisense	pDZ-HA	plasmid.	The	 glycosylation	mutant	primers	were	used	 for	 site	directed	mutagenesis	to	engineer	each	corresponding	mutant	pPol-HA	plasmid	with	the	additional	HA	glycosylation	site	142	or	179.	
Universal Primers Glycosylation Mutant Primers 
Forward primer: 
SapI-F-5’-
GGCCGGCTCTTCTATTAGTAGAAACAAGG-
3’ 
Neth/09-HA142: 
F-5’-GTTCATGGCCCAATCATACCTCGAACAAAGGTGTAACG 
R-5’-CGTTACACCTTTGTTCGAGGTATGATTGGGCCATGAAC 
Reverse primer: 
SapI-R-5’-
CATCGCTCTTCTATTAGCGAAAGCAGG-3’ 
Neth/09-HA179: 
F-5’-TACCCAAAGCTCAACAAATCCTAC 
R-5’-GTAGGATTTGTTGAGCTTTGGG 
 
Reverse genetics techniques were used for the rescue of complete glycosylation mutant 
viruses from plasmid DNA (Palese et al. 1996, Pleschka et al. 1996). A rWT Neth/09 
pPol-HA plasmid (kindly provided by Prof. Adolfo García-Sastre) was used for the 
expression (Neumann et al. 1994) of the glycosylation mutant HA proteins. The 
plasmid contains the viral RNA coding region, flanked by a RNA polymerase I 
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promoter at its 5’ end and a HDV genomic ribozyme at the 3’ end (Figure 16). Two 
individual glycosylation mutant plasmids pPol-HA142 and pPol-HA179 were generated 
by incorporating a single glycosylation site into the rWT Neth/09 pPol-HA plasmid by 
site-directed mutagenesis (Enami et al. 1990) according to the Quikchange site-directed 
mutagenesis kit protocol (Stratagene)14 with a few modifications. The other proposed 
glycosylation mutations were not attempted due to the limited time frame. Single amino 
acid mutations were introduced into the plasmid in a single PCR cycle by using the high 
fidelity Platinum Pfx polymerase (#11708-013, Invitrogen) and the mutant primer pair 
that was designed individually for both glycosylation site mutations (Table 3) and 
ordered from Sigma-Aldrich (New York, USA). The amino acid changes that were 
made in each case to introduce a glycosylation site were D144T for site 142 and S179N 
for site 179. 
4.4 Cloning	
4.4.1 The	pDZ-HA	plasmid	
An expression plasmid pDZ-HA was engineered by subcloning the HA sequence from 
the pPol-HA plasmid (Figure 16) into the pDZ plasmid (Figure 17; kindly provided by 
Adolfo García-Sastre). The HA sequence was inserted between the RNA polymerase 
promoter and terminator sequences of the ambisense pDZ plasmid that allows the 
bidirectional synthesis of both (−) vRNA and (+) mRNA from one viral cDNA template 
essential for viral assembly. The HA sequence was first amplified by a standard PCR 
[92˚C for 2 min, 35 cycles of (94˚C for 30 s, 55˚C for 30 s and 72˚C for 90 s) and 72˚C 
for 7 min] by using universal primers with SapI restriction sites (Table 3). The HA 
segment and the pDZ plasmid were then digested with SapI (#R0569S, New England 
Biolabs) for 1 h at 37˚C and their size was verified on a 1% agarose gel. The HA 
segment was then ligated into the pDZ plasmid with T4 ligase (#M0202S, New England 
Biolabs) using a protocol that involved 2 μl of 10X T4 ligase buffer, ~50 ng of the pDZ 
plasmid, ~100 ng of the HA insert DNA, 2 μl of T4 ligase and H20 up to total volume of 
20 μl with a 30 min incubation at room temperature (RT).  
Chemically competent E. coli cells (prepared by Constanza Martinez Valdebenito) were 
transformed with 5 μl of the ligated plasmid by a general heat shock method, which in 
short involved incubating the plasmid with the cells on ice for 10 min, heat-shocking at 
42˚C for 45 s and cooling on ice for 2 min. The bacteria were then incubated in 500 μl 
of LB broth (#L3022, Sigma-Aldrich) with no antibiotics on a shaker for 1 h at 37˚C, 
                                                          
14 http://www.chem.agilent.com/Library/usermanuals/Public/200518.pdf 
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spread on ampicillin LB plates and grown overnight. One colony was picked on the 
following day and the plasmid was amplified in 200 ml of LB broth with 1 μg/μl 
ampicillin overnight, after which the plasmid DNA was extracted by using the Midiprep 
kit15 (Promega). The pDZ plasmid was engineered for VLP production and other studies 
of Medina laboratory that were not feasible within the time range of this project. 
4.4.2 The	glycosylation	mutant	pPol-HA	plasmids	
The produced glycosylation mutant plasmids pPol-HA142 and pPol-HA179 were 
enzyme-digested with DpnI (#R0176S, New England Biolabs) for 1 h at 37˚C according 
to the Quikchange site-directed mutagenesis kit protocol to digest and eliminate the 
non-mutated, methylated parent pPol-HA plasmids. Chemically competent E. coli cells 
were then transformed with 3 μl of each mutant pPol-HA plasmid DNA by the heat-
shock method described in Chapter 4.4.1. Three representative clones of each of the 
plasmids pPol-HA142 and pPol-HA179 were picked and amplified in 5 ml of LB broth 
(+ 1 μg/ml ampicillin) in a 15-ml culture tube overnight (> 16 h) and the plasmid DNA 
was then extracted by using a Miniprep kit (Promega)16. All the engineered mutant 
plasmids were sequenced (Macrogen, USA) to confirm the correct addition of the single 
glycosylation site and to exclude the possibility of any additional mutations. 
4.5 Rescue	of	the	glycosylation	mutant	viruses	
Rescue of Neth/09-HA142 and Neth/09-HA179 recombinant viruses was attempted 
during this project by using the previously described ambisense system (Hoffmann et al. 
2000a). The engineered pPol-HA142 and pPol-HA179 plasmids were transfected 
together with the Neth/09 pPol-NA plasmid and 6 pDZ ambisense plasmids encoding 
the viral genes and proteins of the PB2, PB1, PA, NP, M and NS segments into 293T 
cells by Lipofectamine® 2000 (#11668-030, Invitrogen) treatment according to 
manufacturer’s instructions17. Additionally, two A/WSN/33 helper pCAGGS protein 
expression plasmids encoding the wild type HA and NA proteins were transfected to aid 
the assembly of the viral particles in the first cycle of viral replication. The pPolI 
plasmid encoding the rWT NA gene, the pDZ expression plasmids and the two helper 
plasmids had been previously generated by the Medina laboratory. 
                                                          
15 
http://fi.promega.com/~/media/Files/Resources/ProtCards/PureYield%20Plasmid%20Midiprep%20Syste
m%20Quick%20Protocol.pdf 
16 
http://fi.promega.com/~/media/Files/Resources/ProtCards/PureYield%20Plasmid%20Miniprep%20Syste
m%20Quick%20Protocol.pdf 
17 http://tools.invitrogen.com/content/sfs/manuals/lipofectamine2000_man.pdf 
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The transfection protocol involved first preparing the plasmid master mix in Optimem® 
that contained standardised concentrations (0.33 μg/transfection reaction) of each of the 
helper and standard plasmids. 250 μl/reaction of this master mix was aliquoted into 
separate tubes (in duplicates) and 0.33 μg of each mutant pPol-HA plasmid was added 
into these master mix aliquots. The plasmid encoding the rWT HA (pPol-HA) was used 
as a positive control for rescuing the glycosylation mutant viruses. Lipofectamine®-
Optimem® mixture was prepared by using 2.5 μl of Lipofectamine® / 1 μg of plasmid 
and was incubated for 5 min in RT. Then each plasmid-Optimem® mix was mixed with 
250 μl/reaction of the Lipofectamine®-Optimem® mix (in duplicates) and incubated for 
20 min at RT. Meanwhile, the 293T cells were trypsinised and a cell suspension 
containing 106 cells/each well was prepared in Optimem®. 1.5 ml of this suspension was 
added into 6-well cell culture plates and the Lipofectamine®-plasmid-Optimem® 
mixtures were then added drop wise into the 293T cell suspension. 22 h post-
transfection MDCK cells were seeded on top of the 293T cells and allowed to grow for 
additional 24 h in DMEM with penicillin/streptomycin, 0.3% bovine albumin and 1 
μg/ml TPCK-treated trypsin (Sigma-Aldrich). Subsequently following this project, the 
supernatants were harvested at 24−36 h post-addition of the MDCKs, then once blind-
passaged to MDCK cells and a plaque assay was simultaneously performed to detect 
virus growth. 
4.6 Virus	propagation	
All viruses were propagated in MDCK cells in T75 tissue culture flasks (Orange 
Scientific). On the previous day prior to infections, the cells were washed twice with 
PBS and detached from the bottom of the flask with 3 ml of 0.05% trypsin (Thermo 
Scientific) at 37˚C for 10−15 min. Cells were then resuspended into complete DMEM, 
seeded into 6-well plates and grown until confluent (~24 h). On the day of infection, the 
cells were first washed twice with PBS to remove the residual serum in the medium that 
inhibits trypsin that is required for progeny virus release from the surface of the infected 
cells. The washed cells were then infected with 200 μl of each virus stock (1:1,000), 
incubated at 37˚C for 1 h and then provided with 2 ml of VGM with additional trypsin 
(1 μg/ml). The cultures were incubated for 48−72 h until the cytopathic effect (CPE) 
was visible and the cell monolayer was detached. The presence of viruses was verified 
by a semi-quantitative hemagglutination assay (Chapter 4.9) and virus-containing 
supernatants were stored in −80˚C for further use. 
46 
 
4.7 Virus	stock	titration	by	plaque	assay	
On the previous day of the infections, the MDCK cells were seeded into 6-well cell 
culture plates as described in the previous chapter. On the day of infection, confluent 
cells were washed twice with PBS and then inoculated with 200 μl of the virus stocks in 
10-fold serial dilutions (10-2–10-7). The cells were infected at 37˚C for 1 h with frequent 
rotation to ensure even infection. The cells were then covered with 2 ml of an optional 
VGM supplemented with 2% of purified agar (#LP0028, Oxoid Ltd.) and 1 μg/ml of 
trypsin and incubated for ≥ 48 h until plaques were visible. Positive plaques were then 
counted and the number of plaque forming units (PFU/ml) was calculated considering 
the dilution at which the plaques were counted and the initial inoculation volume of 
each virus stock. 
4.8 SDS-PAGE	&	Western	blotting	
The viral proteins were verified from whole-cell lysates with polyclonal antibodies by 
Western blot analysis. MDCK cells had been infected at an multiplicity of infection 
(MOI) of 5 for 12 h with the indicated viruses and lysed in NP-40 lysis buffer (50 nM 
Tris, 150 nM NaCl, 5 mM EDTA, 30 mM NaF, 40 mM b-glycerophosphate, 10% 
glycerol and 0.25% NP-40) containing Complete Mini protease inhibitor (Roche). 
Clarified lysates were boiled for 5 min and proteins were separated on two parallel 
SDS-PAGE electrophoresis gradient gels with a 4% stacking gel and a 10% resolving 
gel in the Mini-PROTEAN® Tetra Cell (Bio-Rad)18. The virus preparations were mixed 
with non-reducing SDS-loading buffer and run on the gel with Precision Plus Protein 
Dual Colour ladder (#161-0374, Bio-Rad) for a few hours.  
One of the gels was stained with Coomassie stain (0.25% in 40% methanol and 7% 
acetic acid in dH20) by heating in the microwave for 1 min and incubating for 10 min on 
a rocking plate. The gel was then destained (40% methanol and 7% acetic acid in dH20) 
overnight. The other gel was transferred into a PVDF membrane overnight in the 
chamber provided by the Mini-PROTEAN® Tetra Cell (Bio-Rad). The membrane was 
then blocked with 5% skim milk (#232100, Difco™, BD), 0.5% Tween-20 in 1X PBS 
for 1 h and incubated with 5 ml of a rabbit anti-PR8 headless virus primary antibody 
3951 (1:5,000 dilution) for 1 hour at RT. The membrane was washed three times with 
PBS and incubated for 1 hour in a dilution of 1:10,000 of anti-rabbit IgG-HRP 
conjugate. After washing five times with PBS the membrane was developed with a 
                                                          
18 http://www.bio-rad.com/webroot/web/pdf/lsr/literature/10007296.PDF 
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solution of 10 ml 100 mM Tris, 22 μl of 90 mM coumaric acid, 50 μl of 250 mM 
luminol and 3 μl of 30% H2O2 in a dark room at RT. The membrane was placed under an 
X-ray film in a closed container for 10 min and rinsed with the developing solution and 
H2O. 
4.9 Hemagglutination	(HA)	assays	
 
Materials: 
H1N1 virus stocks 
1X PBS (#BM-1340, Winkler Ltda.) 
0.5% turkey RBCs in 1X PBS 
96-well microplates, V-shape (Nunc) 
 
 
	
Figure	8.	HA-assay	settings.	50	μl	of	PBS	was	added	into	each	well	and	50	μl	of	initial	virus	stock	was	 added	 into	 column	 1.	 Serial	 2-fold	 dilutions	 of	 the	 virus	 (1:2	 up	 to	 1:4,096)	 were	 done	 by	mixing	ten	times	and	by	transferring	50	μl	of	the	virus/PBS	mix	to	the	next	well	across	the	row. 
Influenza A viruses are known to agglutinate α-2,3 SA and α-2,6 SA −expressing red 
blood cells (RBCs) from different species, which leads to the formation of the 
characteristic virus-cell network (Hirst 1942). This property has been used as a 
detection method to confirm the presence of influenza virus in human and animal 
specimens for decades and functions as an excellent preliminary diagnostic method in 
epidemic surveillance and basic research. H1N1 viruses show agglutination of chicken 
RBCs, with the exception of the pH1N1/09 viruses that preferably agglutinate turkey 
RBCs. The hematocrit (% of erythrocytes in whole blood) of turkey blood was 
determined by capillary centrifugation (10,000 rpm for 5 min) and 0.5% RBC solutions 
were prepared in 1X PBS. A V-shaped 96-well plate was prepared for each virus to be 
tested (Figure 8), leaving column 12 as a negative control (PBS only). 50 μl of turkey 
RBCs was then added into all wells and incubated for 30−45 min at 4˚C. The 
hemagglutination units (HAU) of each virus were determined by the last virus dilution 
that showed complete hemagglutination. In the absence of virus the RBCs form a dense 
pellet on the bottom of the well, whereas in the presence of virus a floating virus-RBC 
network is formed and no pellet is observed. Following propagation in MDCK cells, the 
presence of all viruses used in this study was evaluated by this semi-quantitative assay 
prior to further assays. 
48 
 
4.10 Hemagglutination	inhibition	(HI)	assays	
 
Materials: 
H1N1 virus stocks 
1X PBS (#BM-1340, Winkler 
Ltda.) 
05% turkey RBCs in 1X PBS 
96-well microplates, V-shape 
(Nunc) 
trypsin-heat-periodate treated 
mouse and ferret sera 
 
	
Figure	 9.	 HI-assay	 settings.	 25	 μl	 of	 PBS	 was	 added	 into	 each	 well	 except	 column	 1.	 25	 μl	 of	trypsin-heat-periodate	inactivated	sera	were	added	into	column	1	and	serial	2-fold	dilutions	of	the	virus	(1:10	up	to	1:20,480)	were	prepared	by	mixing	ten	times	and	then	transferring	25	μl	of	the	serum/PBS	mix	to	the	next	well	across	the	row.	
HI assay has been used for decades to detect the presence of serotype-specific 
antibodies directed against the HA globular head in animal and human serum (Hirst 
1942). With this simple and quick assay the cross-reactivity of any serotype-specific 
antisera can be evaluated. Mouse sera that had been obtained at 28 days post-infection 
(p.i.) and ferret sera that had been obtained at 21 days p.i. were first trypsin-heat-
periodate inactivated to eliminate the activity of complement and other interfering 
proteins. The inactivation in short involved addition of ½ volume of trypsin into 1 
volume of serum, incubation at 56˚C for 30 min, addition of 3 volumes of 0.011 M 
KIO4, incubation at RT for 15 min, addition of 3 volumes of 1% glycerol saline, 
incubation in RT for 15 min and addition of 2.5 volumes of 85% saline. This treatment 
gave an initial serum concentration of 1:10, from which 2-fold dilutions were prepared 
up to 1:20,480 (Figure 9). The HI assays were performed as described earlier (Salk 
1944). Briefly, the stock viruses were adjusted at titres of HAU 8 by the standard HA 
assay (Chapter 4.9) and mixed with the serial serum dilutions on the plate. The viruses 
were incubated with the sera for 30 min to allow serotype-specific antibody binding, 
after which 50 μl of turkey RBCs were added. After 30−60 min incubation in RT the HI 
titres were determined by visual examination as the last serum dilution that completely 
inhibited hemagglutination of RBCs. 
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4.11 Serology	ELISA	
Serology ELISA was utilised to measure the level of IgG antibodies in antisera from 
mice infected with the recombinant glycosylation mutant viruses. Immulon® 4 HBX 
ELISA plates (Nunc) were covered with 100 μl of each serial 2-fold dilution 
(1:2,000−1:64,000) in quadruplicates of trypsin-heat-periodate inactivated mouse sera 
that had been raised against rWT Neth/09, Neth/09-HA144, Neth/09-HA144-172, 
Neth/09-HA71-142-177 or Neth/09-HA71-142-172-177 mutant viruses. Following 
overnight incubation at 4˚C the wells were washed three times with 200 μl of 1X PBS 
and then blocked for 1 h in RT with 100 μl of the blocking medium that contained 5% 
skim milk (#232100, Difco™, BD), 0.05% Tween-20 and 5% sheep serum in 1X PBS. 
They were then incubated with 50 μl of a 1:5,000 dilution of Gt X Ms IgG γ chain-
specific antibody (#AP503P, Millipore) in the blocking medium for 1 h in RT. 100 μl of 
a 1:1 mixture of HRP substrate solutions A and B (Kirkegaard & Perry Laboratories 
KPL) was added into each well and the absorbance at each serum dilution was measured 
at λ 405 on a microplate reader (PHOMO, Autobio Labtec Instruments). 
4.12 Microneutralisation	assays	
In this assay the presence of serotype-specific nAbs in antisera collected from mice at 
28 days p.i. and from ferrets at 21 days p.i. infected with the rWT or the Neth/09-
HA144 glycosylation mutant viruses was determined. The microneutralisation assay 
was modified from WHO Influenza Manual (WHO Global Influenza Surveillance 
Network 2011) and consists of three sections: 1) virus-antibody reaction step, 2) 
inoculation step and 3) serology ELISA. 
4.12.1 Determination	of	tissue	culture	infectious	dose	50	
The virus stocks were first titrated for the tissue culture infectious dose (TCID50) 
according to the 2011 WHO Influenza Manual (WHO Global Influenza Surveillance 
Network 2011). Briefly, MDCK cells were seeded on 96-well cell culture plates 
(Orange Scientific) in VGM at 2 x 105 cells/ml and grown until the cell monolayer was 
75% confluent (~24 h). Cells were then inoculated with ½log10 serial virus dilutions 
from 10-2 to 10-7 (Figure 10). TCID50 of each glycosylation mutant virus was calculated 
by the Reed & Muench method (Figure 11). 
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Figure	10.	Virus	stock	 titration	 for	 the	microneutralisation	assay.	100	 μl	of	VGM	was	added	into	each	well	except	column	1.	146	μl	of	the	initial	10-2	dilution	was	added	into	the	wells	of	the	first	column	and	serial	½log10	dilutions	were	prepared	across	the	plate	by	 transferring	46	μl	 into	 the	next	column.	This	virus	preparation	was	inoculated	into	cells	that	had	been	seeded	on	96-well	cell	culture	plate	at	2	x	105	cells/ml	on	the	previous	day.	
 
Figure	11.	Determination	of	the	TCID50	of	the	virus	stocks	for	the	microneutralisation	assay.	The	 equations	 for	 calculating	 the	 tissue	 culture	 infectious	 dose	 50	 (TCID50)	 of	 influenza	 stocks,	modified	from	(WHO	Global	Influenza	Surveillance	Network	2011). 
 
The titration of Neth/09-HA144 is presented here as an example: 
Proportional distance = ଵ଴଴%ିହ଴	୶	଴.ହ
	ଵ଴଴%ିଶ଴% = 0.3125	
TCID50 = 104+0,3 = 104,3 TCID50 / 100 μl (initial inoculation volume) = 105,3 TCID50 / ml 
= 1,99 x 105 TCID50 / ml. 100 x TCID50 for this virus is 0.50 μl of the virus stock / well, 
which equals 48 μl / 96-well plate (a 1:100 dilution). 
%	positive	value	above	50% − 50	x	0.5	(correction	factor	for	½log10	dilutions)
%	positive	value	above	50% −%	positive	value	below	50%  
Proportional distance:  
TCID50:                dilution	that	gives	 > 50%	positive	wells + proportional	distance 
In the microneutralisation assay 100 x TCID50 was used, for which the required volume of the stock 
virus was calculated by using the following equation: 
100 x TCID50:								
ଵ଴଴଴	ஜ୪	୶	ଵ଴଴
୘େ୍ୈ	ହ଴/୫୪ = X	μl	of	virus	stock/well 
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4.12.2 Virus-serum	inoculation	&	serology	ELISA	
Microneutralisation assay involved seeding the MDCK cells on sterile 96-well cell 
culture plates (Orange Scientific) at 2 x 105 cells/ml. The cells were incubated until the 
cell monolayer was > 75% confluent (~24 h). Mouse and ferret antisera was inactivated 
at 56˚C for 30 min and 2-fold serial dilutions were prepared of each serum in 
quadruplicates on a separate sterile 96-well cell culture plate (Figure 12). 100 x TCID50 
of the virus stocks were added into each well and was incubated with the antisera for 1 h 
at 37˚C to allow serotype-specific antibody binding. The cells were then inoculated with 
the virus-serum mixture by direct transfer from the mixing plate and incubated for 
18−20 h at 37˚C, after which a serology ELISA was performed. 
 
Figure	12.	Microneutralisation	assay	test	settings.	2	x	105	cells/ml	were	seeded	on	a	sterile	96-well	plate	and	incubated	for	~24	h.	On	a	separate	sterile	mixing	plate,	50	μl	of	VGM	was	added	into	each	well	except	90	μl	into	column	1.	10	μl	of	heat-inactivated	mouse	and	ferret	sera	were	added	in	column	 1	 in	quadruplicates	and	 serial	2-fold	dilutions	 (1:10−1:10,240)	were	prepared	by	mixing	ten	times	and	then	transferring	50	μl	of	the	serum/VGM	mix	to	the	next	well	across	the	row.	100	x	TCID50	was	added	 into	 each	well	except	 the	 cell	 control	wells	and	 this	 serum-virus	mixture	was	incubated	at	37˚C	for	1	h	prior	to	inoculation	into	the	cells.	
The cells were fixed with ice-cold 80% acetone in PBS for 30 min, air-dried and washed 
with 200 μl of PBS, after which they were incubated with an α-NP protein primary 
antibody (1:5,000) in PBS / 0.3% Tween-20 / 5% skim milk (#232100, Difco™, BD) 
diluent for 1 h at RT. After three washes (PBS + 0.3% Tween-20) the cells were 
incubated with a secondary antibody α-rabbit HRP conjugate (1:10,000) in the diluent 
for 1 h in RT, washed five times with the wash buffer and developed with 100 μl of a 
1:1 HRP substrate mixture A and B (Kirkegaard & Perry Laboratories KPL) for ≥ 1 h. 
Absorbance was measured at λ 450 on a microplate reader (PHOMO, Autobio Labtec 
Instruments). Neutralisation titres are represented as the geometrical mean of the highest 
serum dilution that was able to neutralise infection. 
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5 Results	
5.1 Seasonal	H1N1	human	viruses	acquired	HA	globular	head	
glycosylation	sites	over	time	
 
Figure	13.	HA1	domain	alignment	of	the	natural	seasonal	H1N1	isolates	between	1918	and	
2009.	Light	blue-coloured	shading	depicts	the	known	antigenic	sites	listed	on	the	top	and	dark	blue	boxes	represent	glycosylations	that	appeared	and	disappeared	over	time,	predicted	by	the	N-X-S/T	motif.	Antigenic	sites	corresponding	H3	numbering:	Cb	(78−83),	Sa	(128–129,	156–160,	162–167),	Sb	(187–198),	Ca1	(169–173,	206–208,	238–240)	and	Ca2	(140–145,	224–226)	(Manicassamy	et	al.	2010b).	Arrows	on	 the	 right	point	 the	 year	 glycosylations	 appeared	 at	 the	 indicated	 amino	 acid	residues.	 Sequences	were	obtained	 from	 Influenza	Research	Database,	 alignment	was	done	with	ClustalW	and	manual	editing	was	done	with	BioEdit	software. 
Among other mutations, the H1 HA has acquired site-specific N-linked glycosylations 
at amino acid residues 71, 142, 144, 172, 177 and 179 over the past decades. These 
glycosylations have appeared and disappeared gradually in the HA globular head 
antigenic sites and have become fixed in time in the naturally occurring seasonal H1N1 
strains (Figure 13), which may indicate their selective advantage on the viral antigenic 
profile (Medina et al. accepted). The analysis concentrates around the HA1 antigenic 
sites of seasonal H1N1 isolates, which were sequenced to confirm that no additional 
mutations arouse after passage in MDCK cells. Notably, there are no human influenza 
sequences available between 1918 and 1933 and most of the sequences are from strains 
that have been passaged extensively in eggs and/or nonhuman mammalian laboratory 
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cell cultures. The alignment shows that during the years 1935 to 1957, three different 
HA glycosylations were acquired sequentially at residues 144, 172 and 177. The 
emergence of the H2N2 pandemic influenza virus in 1957 displaced the H1N1 viruses, 
which disappeared from human circulation. The H1N1 virus strain re-emerged in 
humans in 1977 and contained the same HA glycosylation sites as the H1N1 viruses 
circulating in the 1950’s. In 1986, glycosylation site 144 was replaced by glycosylations 
on positions 71 and 142. However, in 1987 glycosylation site 172 was lost, and since 
then the circulating H1N1 viruses contained glycosylation sites 71, 142 and 177 in the 
HA globular head. Since the glycosylation status of the pH1N1/09 is the same as that of 
the pH1N1/18, the pH1N1/09 virus has the potential to acquire the same or similar 
glycosylations over time as a result of immune selection pressure.  
Table	4.	Glycosylation	models	of	HA	monomers	of	natural	H1N1	isolates	between	1918	and	
2012.	Potential	glycosylation	sites	 (N-X-S/T	motif)	 indicated	with	arrows	and	 the	number	of	 the	amino	acid	residue.	The	conserved	glycosylation	sites	N27,	N40	and	N104	are	present	in	all	viruses.	A/California/04/2009	 was	 used	 as	 a	 model	 (PDB	 ID:	 3LZG),	 the	 sequence	 was	 obtained	 from	Influenza	 Research	 Database	 and	 images	 were	 created	 with	 PyMol	 Molecular	 Graphics	 System,	version	1.1eval.	
 
The antigenic HA1 globular head has acquired multiple different glycosylation sites 
(Table 4) along with antigenic drift, while the glycosylation status of the antigenically 
less prominent stem HA2 has remained highly conserved (Sun et al. 2011). These 
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specific HA globular head glycosylation sites seem to have been important for the 
evolution of influenza A viruses, which justifies further evaluation of their 
immunomodulatory role within the experimental part of this thesis.  
5.2 Hemagglutinin	expression	levels	of	glycosylation	mutant	viruses	
are	similar	
 
Figure	14.	Hemagglutinin	 expression	 levels	 of	 recombinant	 viruses	with	 single	 or	double	
additional	 glycosylation	 sites.	 a)	 A	 Coomassie-stained	 SDS-PAGE	 (4%	 stacking	 gel	 and	 10%	resolving	 gel)	 of	 the	 glycosylation	 mutant	 viruses	 with	 the	 indicated	 HA	 glycosylation	 sites.	 b)	Western	blot	of	the	glycosylation	mutant	viruses	with	the	indicated	HA	glycosylation	sites.	Primary	Ab:	α-PR8	headless	virus,	secondary	Ab:	α-rabbit	IgG-HRP	conjugate,	exposure	time:	10	min.	
Virus preparations had been made by propagating the rWT and glycosylation mutant 
viruses into high titres in MDCK cells. The supernatants were harvested and pelleted by 
20% sucrose cushion ultracentrifugation (at Universidad de Santiago de Chile). The 
resulting virus pellets were resuspended in NP-40 containing Complete Mini protease 
inhibitor. The virus preparations were boiled for 5 min and analysed on two parallel 
SDS-PAGE electrophoresis gels, one of which was stained with Coomassie stain and 
the other of which was transferred into a Western blot membrane and developed on an 
X-ray film. Similar HA bands can be seen both on the Coomassie-stained (Figure 14: A) 
and the Western blot (Figure 14: B) for the studied glycosylation mutant viruses, 
although the band for the Neth/09-HA172 seems to be slightly weaker than for the other 
viruses. The results suggest that these glycosylations are utilised by the virus and that 
roughly similar amounts of HA are assembled into the virus particles. 
5.3 Neth/09	glycosylation	mutant	viruses	elicit	equal	IgG	responses	in	
mice	
IgG antibody responses induced in mice infected with recombinant mutant viruses with 
1−4 glycosylations were tested in an ELISA serology assay by using a Gt X Ms IgG γ 
chain-specific antibody. A 1:1 mixture of peroxidase substrate solutions A and B was 
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used for colorimetric visualisation of IgG presence in the antisera and the absorbance 
was measured at λ 405. The dilution factor represents the reciprocal of each mouse 
serum dilution used. It can be seen that the observed IgG response is very similar for all 
rWT, Neth/09-HA144, Neth/09-HA71-142-177 and Neth/09-HA71-142-172-177 
viruses assessed in this study, although the Neth/09-HA71-142-177 seems to have 
slightly lower antigenicity in mice, as compared to the rWT (Figure 15). 
  
Figure	 15.	 IgG	 antibody	 response	 against	 the	 glycosylation	 mutant	 viruses	 with	 1−4	
additional	 glycosylations.	 Mice	 had	 been	 infected	 with	 the	 recombinant	 Neth/09	 viruses	containing	the	indicated	HA	mutations;	71-3	=	Neth/09-HA71-142-177	and	71-4	=	Neth/09-HA71-142-172-177.	Mouse	antisera	were	tested	at	dilutions	1:2,000−1:64,000	with	a	1:5,000	dilution	of	a	Gt	X	Ms	IgG	γ	chain-specific	antibody.	
5.4 Glycosylation	site	144	in	the	pandemic	H1N1	virus	background	
broadens	the	humoral	immune	response	in	mice	
The sera from mice and ferrets infected with rWT and recombinant mutant viruses with 
variable glycosylation levels were tested in HI assays (Chapter 4.10) against the 14 
previous natural seasonal H1N1 isolates (Table 2) and each other for their 
hemagglutination inhibitory activity (HI titre). All viruses were propagated in MDCK 
cells to high titres (HAU ≥ 16), titrated by plaque assays and tested against trypsin-heat-
periodate −treated mouse and ferret sera. Mouse antisera were pooled from multiple 
animals that had a homologous HI titre of 160, except for the highly immunogenic rWT 
virus that had constantly higher homologous titres (HI = 320) than the mutant viruses. 
The glycosylation mutant virus ferret antisera that were used for the assays were from a 
single selected animal that had a homologous serum HI titre of 320. All viruses were 
standardised by an HA assay (Chapter 4.9) at HAU = 8 prior to the HI assay. HI titre 
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was considered as the last serum dilution that completely inhibited hemagglutination of 
0.5% turkey RBCs.  
Table	 5.	 HI	 titres	 of	 mouse	 and	 ferret	 sera	 after	 infection	 with	 rpH1N1/09	 glycosylation	
mutant	 viruses	 against	 natural	 seasonal	 H1N1	 isolates	 from	 1930−2009.	 The	 HA1	glycosylation	 sites	of	 the	natural	 seasonal	H1N1	 isolates	were	predicted	 from	 the	HA	 sequences	(Influenza	Research	Database)	based	on	the	N-X-S/T	motif.	Mice	and	ferrets	had	been	infected	with	the	 recombinant	 Neth/09	 viruses	 containing	 the	 indicated	 HA	 mutation.	 HI	 titres	 represent	 the	reciprocal	of	the	highest	dilution	that	completely	inhibited	hemagglutination	of	0.5%	turkey	RBCs.		
SEASONAL H1N1 VIRUSES MOUSE SERUM FERRET SERUM 
Isolate 
HA1 
glycosylation 
sites 
rWT 144 rWT 144 144-172 
A/Swine/Iowa/30 − < 10 20 < 10 < 10 < 10 
A/PR/8/34 144 < 10 < 10 < 10 < 10 < 10 
A/Weiss/43 144, 179 < 10 10 < 10 < 10 < 10 
A/FLW/52 144, 172, 177 < 10 < 10 < 10 < 10 < 10 
A/Denver/57 172, 177 < 10 20 < 10 < 10 < 10 
A/USSR/92/77 144, 172, 177 < 10 20 < 10 < 10 < 10 
A/USSR/46/79 144, 172, 177 < 10 10 < 10 < 10 < 10 
A/Finland/13/80 144, 172, 177 < 10 < 10 < 10 < 10 < 10 
A/Houston/84 144, 172, 177 < 10 < 10 < 10 < 10 < 10 
A/Texas/36/91 71, 142, 177 < 10 10 < 10 < 10 < 10 
A/NewCal/20/99 71, 177 < 10 10 < 10 < 10 < 10 
A/Brisbane/59/07 71, 142, 177 < 10 < 10 < 10 < 10 < 10 
A/California/07/09 − 320 < 10 1,280 320 320 
A/Netherlands/602/09 − 320 160 1,280 320 320 
 
None of the previously produced mouse or ferret antisera showed cross-reactivity 
among the natural seasonal H1N1 isolates (Table 5) when assessed by two or more 
individual HI assays. When antisera from mice that had been infected with mutant 
viruses with a single additional glycosylation site were evaluated, only the Neth/09-
HA144 was shown to have elicited broadly reactive antibodies that were capable of 
cross-reacting with all the rWT and glycosylation mutant viruses above homologous 
titres (Table 6). Conversely, all the rWT and glycosylation mutant virus antisera 
consistently lost their reactivity against the Neth/09-HA144 virus (Table 6). Infection 
with other recombinant mutant viruses with a single additional HA glycosylation site 
lead to narrowed cross-reactive responses in mice, as compared to their homologous 
titres (Table 6). The breadth of polyclonal response elicited in mice by recombinant 
mutant viruses with multiple (1−4) additional HA glycosylations was also evaluated. 
The Neth/09-HA144-172 was the only virus of the polyglycosylated mutant viruses that 
was shown to elicit polyclonal antibodies in mice, capable of cross-reacting with all the 
rWT and glycosylation mutation viruses (Table 7). Conversely, all rWT and 
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glycosylation mutant virus antisera consistently lost their reactivity against this virus. 
Other polyglycosylated viruses were not shown to broaden this response above 
homologous titres in this study (Table 7). 
Table	6.	HI	titres	of	mouse	sera	after	infection	with	rpH1N1/09	mutant	viruses	with	a	single	
additional	 HA	 glycosylation.	 Mice	 had	 been	 infected	 with	 recombinant	 Neth/09	 viruses	containing	the	indicated	HA	mutation.	HI	titres	represent	the	reciprocal	of	the	highest	dilution	that	completely	 inhibited	hemagglutination;	homologous	 titres	are	 in	bold	and	shaded.	The	 titres	 that	are	presented	 in	 italics	were	obtained	 in	 the	previous	study	of	Medina	 laboratory	 (Medina	et	 al.	accepted)	but	were	all	re-evaluated	and	verified	during	this	project.	
VIRUS 
MOUSE SERUM 
rWT 142 144 172 177 
rWT 320 80 320 80 80 
142 160 160 640 160 160 
144 10 < 10 160 < 10 < 10 
172 320 160 320 320 320 
177 640 80 320 80 80 
71-142 160 80 320 40 80 
144-172 20 < 10 80 10 < 10 
71-142-177 80 160 160 40 80 
71-142-172-177 160 80 160 160 40 
	
Table	7.	HI	titres	of	mouse	sera	after	infection	with	rpH1N1/09	mutant	viruses	with	multiple	
additional	 HA	 glycosylations.	 Mice	 had	 been	 infected	 with	 recombinant	 Neth/09	 viruses	containing	the	indicated	HA	mutations.	HI	titres	represent	the	reciprocal	of	the	highest	dilution	that	completely	 inhibited	hemagglutination;	homologous	 titres	are	 in	bold	and	shaded.	The	 titres	 that	are	presented	 in	 italics	were	obtained	 in	 the	previous	study	of	Medina	 laboratory	 (Medina	et	 al.	accepted)	but	were	all	re-evaluated	and	verified	during	this	project.	
VIRUS 
MOUSE SERUM 
71-142 144-172 71-142-177 
71-142-
172-177 
rWT 80 160 40 20 
142 160 640 320 320 
144 < 10 80 < 10 < 10 
172 160 1,280 160 80 
177 80 320 20 40 
71-142 320 640 160 320 
144-172 < 10 160 < 10 40 
71-142-177 320 160 160 160 
71-142-172-177 80 320 160 160 
	
Due to the broadened cross-reactivity observed in mice for the Neth/09-HA144 mutant 
virus, HI assays were extended into ferrets to further study the effect of incorporating 
additional glycosylation sites 144 and 144-172 into the pandemic Neth/09 virus 
background. Contrary to our expectations, antisera from ferrets infected with the 
Neth/09-HA144 or Neth/09-HA144-172 were shown to be incapable of cross-reacting 
with the rWT and a panel of recombinant mutant viruses with variable glycosylation 
levels (Table 8). In effect, these additional HA glycosylations were shown to narrow the 
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humoral immune response ≥ 2-fold lower than homologous levels for both assessed 
recombinant mutant viruses against a panel of mutant viruses with variable 
glycosylation levels (Table 8). 
Table	8.	HI	titres	of	ferret	sera	after	infection	with	pH1N1/09	glycosylation	mutant	viruses.	Ferrets	 infected	with	 recombinant	pandemic	Neth/09	viruses	containing	 the	 indicated	additional	HA	mutation.	HI	 titres	 represent	 the	 reciprocal	 of	 the	highest	dilution	 that	 completely	 inhibited	hemagglutination;	homologous	titres	are	in	bold	and	shaded.		
VIRUS 
FERRET SERUM 
rWT 144 144-172 
rWT 1280 320 320 
142 320 320 160 
144 160 640 320 
172 80 80 160 
177 1280 320 160 
71-142 80 80 80 
144-172 20 20 320 
71-142-177 320 160 320 
71-142-172-177 40 20 160 
 
5.5 rNeth/09	virus	with	144	glycosylation	elicits	antibodies	capable	of	
neutralising	the	rWT	virus	in	mice	
Microneutralisation assays were performed on MDCK cells with mouse and ferret sera 
against the rWT and Neth/09-HA144 mutant viruses. TCID50 of both viruses was 
determined prior to the microneutralisation assay by Reed-Muench method according to 
the WHO Manual (WHO Global Influenza Surveillance Network 2011). 100 x TCID50 
of both virus was tested against mouse and ferret sera at 2-fold serial serum dilutions 
(1:10−1:10,240). Infections were detected by incubation with a rabbit polyclonal α-NP 
antibody (1:5,000) and a secondary α-rabbit-HRP conjugate antibody (1:10,000). 
Positive wells were visualized with a HRP substrate at λ 450 nm. Neutralisation titres 
are represented as the reciprocal of the geometrical mean of the highest serum dilution 
that displayed neutralisation activity. Infection with the Neth/09-HA144 was shown to 
neutralise both rWT and Neth/09-HA144 viruses and the rWT antiserum was shown to 
have remarkably lost its reactivity against the Neth/09-HA144 virus (Table 9). 
However, in ferrets the infection with Neth/09-HA144 lead to 4-fold loss in 
neutralisation activity against the rWT virus and the rWT antiserum retained its 
reactivity against both rWT and Neth/09-HA144 viruses (Table 9). 
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Table	9.	Microneutralisation	assay	of	 rWT	Neth/09	and	Neth/09-HA144	viruses.	Titres	are	represented	as	geometrical	mean	of	the	highest	serum	dilution	that	was	able	to	neutralise	infection.	Neutralisation	titres	of	the	ferret	sera	were	obtained	within	this	project	and	titres	of	the	mouse	sera	were	obtained	subsequently	by	the	Medina	laboratory	(Medina	et	al.	accepted).	
 MOUSE SERUM FERRET SERUM 
VIRUS rWT 144 rWT 144 
rWT 320 320 1280 640 
144 80 480 1280 2560 
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6 Discussion	
N-linked glycosylations of the HA surface glycoprotein are believed to have an 
important role in altering the antigenicity, virulence and receptor-binding properties of 
influenza A viruses. The significance of these oligosaccharides has been studied in 
various recent studies but the detailed molecular determinants of the antigenicity remain 
unrevealed. Within this Master’s thesis project the HA1 protein domains of the natural 
seasonal H1N1 isolates from years 1930−2012 were analysed by commonly used 
sequence alignment tools. This revealed that N-linked glycosylations 71, 142, 144, 172, 
177 and 179 in the HA globular head are naturally occurring in the H1N1 isolates 
(Figure 13). Based on their constant appearance near or within the major HA antigenic 
regions − Sa, Sb, Cb, Ca1 and Ca2 − it was suggested that these post-translational 
modifications are likely to have an important role in antigenic evolution of H1N1 
influenza A viruses. Their significance for influenza A antigenicity and impact on the 
breadth of humoral immune response was assessed by virological and serological in 
vitro methods. 
 
Mice, cotton rats, hamsters, macaques, ferrets and guinea pigs have been widely used as 
model animals to study influenza virus immunogenicity, virulence and therapeutical 
applications [reviewed in (Bouvier & Lowen 2010)]. Mice and ferrets are the most 
common models and are also utilised by the Medina laboratory. The seasonal 
glycosylated H1N1 viruses need to be laboratory-adapted and do not generally produce 
human-like disease in mice, which is in strong contrast with the pH1N1/18 and 
pH1N1/09 strains, certain subtype H7 viruses and the highly pathogenic avian influenza 
H5N1 viruses that do not require adaptation and are lethal at low doses. In mice 
influenza viruses replicate to high titres, causing tissue damage in the LRT and lethargy 
that can lead to hypothermia. Ferrets are highly susceptible to the seasonal human 
H1N1 viruses that primarily replicate to high titres in the URT but not in the LRT. 
Ferrets get human-like illness that involves sneezing, nasal discharge, coughing, 
lethargy, anorexia and fever and are therefore considered to represent human illness 
most accurately. Since they are bigger animals than rodents, larger volumes of post-
infection serum can be obtained without the need to sacrifice the animal. These 
characteristics justify the use of these model animals in this study. The use of animal 
models to study influenza pathogenicity and transmission is reviewed in (Bouvier & 
Lowen 2010). 
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A recent study by Medina and colleagues demonstrated that HA globular head 
glycosylations play an important role in modulating the pathogenesis and the antigenic 
properties of the pH1N1/09 virus (Medina et al. accepted). Recombinant pandemic 
H1N1 A/Netherlands/602/09 (rWT Neth/09) viruses were generated by incorporation of 
multiple additional HA globular head glycosylations to mimic their temporal 
appearance in the natural seasonal H1N1 isolates. The addition of multiple 
glycosylations on the non-glycosylated HA globular head of the rWT Neth/09 was 
shown to attenuate the virulence of this virus in vivo but not in vitro. It was shown that 
each virus had a reduced amount of HA incorporated into the virions compared to the 
rWT. However, additional glycosylations did not seem to affect infectivity since all 
viruses replicated at titres equal to the original WT Neth/09 isolate (> 107 pfu/ml) in 
human tracheobronchal epithelial (HTBE) cells. Glycosylation-dependent decrease in 
pathogenicity and severe attenuation was observed in mice and ferrets for all viruses 
with two or more additional glycosylations, as observed by weight loss. However, the 
Neth/09-HA144 virus was shown to have weight loss patterns similar to the rWT in 
mice, which indicates that this glycosylation does not seem to impair the virulence of 
the pH1N1/09 virus. 
In the above mentioned study (Medina et al. accepted) by the Medina laboratory, 
incorporation of an additional glycosylation site at residue 144 alone (Table 6 of this 
thesis) or together with glycosylation at site 172 (Table 7 of this thesis) in the non-
glycosylated rWT pH1N1/09 virus background was shown to broaden the humoral 
immune response in mice and showed improved cross-reactivity against the rWT and a 
panel of recombinant mutant Neth/09 viruses with multiple glycosylations. Conversely, 
the rWT mouse antiserum remarkably lost its reactivity against both viruses containing 
the 144 glycosylation as compared to its homologous titre, while cross-protection was 
retained against other glycosylation mutant viruses. The impact of this glycosylation on 
the antigenicity of the rWT virus had been further assessed in microneutralisation 
assays. Glycosylation site 144 in the pandemic H1N1 background was shown to induce 
polyclonal responses capable of neutralising both the rWT and 144-glycosylated virus at 
similar levels, whereas the rWT antiserum lost its reactivity against the 144-
glycosylated virus to 4-fold lower than homologous titres. These findings suggest that 
the site 144 masks an important antigenic epitope, which redirects the polyclonal 
response to other sites within or around the antigenic site Sa. 
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In the same study by Medina and colleagues the significance of HA globular head 
glycosylations was demonstrated by modifying a recent seasonal H1N1 strain 
A/Texas/36/91 (Tx/91) that has three naturally occurring HA1 glycosylation sites − 71, 
142 and 177. The deletion of all these glycosylation sites from this strain lead to 
production of antibodies that protected from the antigenically distant rWT Neth/09 and 
resulted in increased pathogenicity (as measured by weight loss) in mice, compared to 
the rWT Tx/91. The highest morbidity was observed for the Δ71-142-177 virus that 
resembles the rWT Neth/09 in that both have a non-glycosylated HA head, which 
demonstrates that HA glycosylations negatively affect the pathogenicity of human 
H1N1 viruses. The potential of these glycosylation deletion viruses to elicit cross-
reactive antibodies against the rWT Neth/09 was also assessed in mice. Mice were first 
infected with the rWT Tx/91 or one of the glycosylation deletion Tx/91 viruses (∆71, 
∆71-177 or Δ71-142-177) and then challenged at 27 days p.i. with 100 x LD50 of rWT 
Neth/09 virus. Mice initially infected with the Tx/91 ∆71 had a survival rate of 20%, 
whereas mice infected with Tx/91 ∆71-177 or Δ71-142-177 all survived but suffered a 
weight loss of up to ~20%. The mice initially infected with the Δ71-142-177 showed 
overall lowest morbidity level after rWT Neth/09 challenge. These observations suggest 
that HA glycosylations mask the antigenic sites and that the equal glycosylation status is 
responsible for the cross-reactive antibodies elicited by these antigenically distinct 
viruses. 
The cross-reactivity of antisera from humans vaccinated with the monovalent 
inactivated pH1N1/09 vaccine against a panel of glycosylation viruses was assessed in a 
vaccine study by the same research group described above (Medina et al. accepted). The 
authors report that most of the paediatric (< 18 years of age) and adult individuals had 
detectable antibody levels against the mutant viruses but the lowest HI titre was 
observed against the viruses with 144 and 144-172 glycosylations. This observation 
confirms the results obtained from the mouse cross-reactivity studies and verifies the 
immunomodulatory masking effect of the additional glycosylation site 144. It was also 
seen that the antisera from patients vaccinated with the trivalent seasonal H1N1/09 
vaccine did not have cross-reactivity against the glycosylated mutant viruses, 
independent on their glycosylation status. This was expected since that vaccine 
composition contained a previously circulating seasonal H1N1 strain.  
Previous studies have demonstrated the glycosylated viruses to be more sensitive to 
innate immune activity of collectins present in lung fluid but to retain their ability to 
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replicate efficiently in mouse airway macrophages and in MDCKs in vitro (Vigerust & 
Shepherd 2007, Tate et al. 2011). The number and position of glycosylation sites plays 
an important role in attenuation (Hillaire et al. 2012), which was also demonstrated in 
the study by Medina and colleagues since some mutations resulted in attenuated 
phenotype (eg. sites 142 & 172) while others did not (site 177) (Medina et al. accepted). 
When naïve ferrets were infected with rWT and 144-172 viruses, differences in viral 
load were observed in lungs and trachea of the 144-172 infected animals but not in nasal 
turbinates. The glycosylated H1N1 viruses were able to replicate in URT (nose) at 
similar levels as the rWT but low viral titres were observed in LRT (trachea and lungs). 
These results suggest that selection of glycosylated influenza viruses may be affected by 
both pre-existing nAbs and the activity of collectins. However, the outcome of influenza 
infection seems to be further complicated by the presence of numerous other factors, 
whose role is to be verified by further in vivo assessments in both influenza animal 
models. The interactions between these factors and N-linked glycans on the surface of 
HA protein are likely to function in complex, yet fully uncovered co-operation. 
This Master’s thesis project continues from the results obtained in the Medina 
laboratory (summarised ahead in this chapter) and aims at further assessing the impact 
of the naturally occurring glycosylations by virological and serological in vitro 
methods. Along with this project, Medina laboratory was relocated from New York 
(USA) to Santiago (Chile) and therefore all methods, cell culture and assays were 
simultaneously set up, revised and optimised. Initially, we proposed to engineer five 
glycosylation mutant viruses Neth/09-HA71, Neth/09-HA142, Neth/09-HA172, 
Neth/09-HA177 and Neth/09-HA179 by reverse genetics methods and to infect mice 
with these viruses during this project to obtain glycosylation mutant virus-specific 
antisera to be used in further cross-reactivity studies. However, due to challenges with 
cell contamination and method optimisation, these aims could not be completed within 
the timeline of this project. However, rescue of two glycosylation mutant viruses, 
Neth/09-HA142 and Neth/09-HA179, was attempted and preliminary analyses 
performed outside of this project suggest these rescues to have been successful. 
Fortunately, all animal sera, the rWT virus and glycosylation mutant viruses had already 
been previously produced by the Medina laboratory and were very kindly provided for 
the assays of this thesis.  
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Cross-reactivity assays with the rWT mouse and ferret sera, Neth/09-HA144 mouse and 
ferret sera and Neth/09-HA144-172 ferret serum were conducted against the 14 natural 
seasonal H1N1 isolates by HI assays. Each glycosylation mutant serum showed poor 
cross-reactivity against the tested strains with no major differences among the isolates 
(Table 5). The results suggest that the poor cross-reactivity is likely due to the major 
amino acid changes that occurred during the evolution of H1N1 viruses around and 
outside the antigenic regions, rather than due to the glycosylation status of the HA 
globular head. Therefore the level of cross-reactivity observed between any two strains 
is most likely to be influenced by the overall similarity of their HA amino acid sequence 
and not only the level of HA glycosylations. However, these titres were obtained from 
single experiments and HI assay only reveals the presence of serotype-specific nAbs in 
a serum but fails to give information on their ability to prevent an infection in vitro. 
Further microneutralisation assays will be needed to retrieve information on the 
neutralisation ability of the anti-rWT, anti-Neth/09-HA144 and anti-Neth/09-HA144-
172 antisera against the natural seasonal H1N1 isolates. 
 
Due to the close proximity of site 142 to site 144, we were also interested in assessing 
whether an additional glycosylation at this site in the non-glycosylated rpH1N1/09 
background has a similar effect on cross-reactivity as does glycosylation at residue 144. 
Interestingly, incorporation of an additional glycosylation at site 142 did not lead to 
similar broadened cross-reactivity that has been observed for site 144 with mouse 
antiserum (Table 6), despite of its nearby location within the antigenic site Sa. 
Surprisingly, the Neth/09-HA144-172 had 4-fold increased cross-reactivity against the 
Neth/09-HA172 virus (Table 7), which suggests that additional glycosylation site 172 
might be responsible for the broadened reactivity. However, addition of glycosylation 
site 172 alone (Table 6) or in the context of the Neth/09-HA71-142-172-177 virus 
(Table 7) did not increase cross-reactivity above homologous titres. This confirms that 
glycosylation site 172 alone is not likely to be responsible for the broadened cross-
reactivity observed for the Neth/09-HA144-172 virus but seems to require co-operation 
with glycosylation site 144 to acquire this feature.  
Interestingly, both mouse (Table 6) and ferret rWT antisera (Table 8) gave a very high 
HI titre against the Neth/09-HA177 virus, which indicates strong antigenic similarity 
between rWT and Neth/09-HA177. Consequently, this glycosylation site does not seem 
to shield any major antigenic epitopes from antibody recognition but may actually 
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improve the accessibility of the epitopes by unmasking the antigenic site Sa. In the 
future it would be interesting to further evaluate the impact of glycosylation site 177 
and the neighbouring site 179 on the breadth of humoral response in mice and ferrets. 
Based on the observations with the Neth/09 glycosylation mutant virus antisera, the 
single additional HA glycosylations, with the exception of site 144, all seem to narrow 
the polyclonal response (Table 6) by slightly altering the focus of antigen recognition 
possibly around site Sa. Of the potential glycosylation sites examined, amino acid 
residue 144 seems to be the only site where additional N-linked glycosylation broadens 
the cross-reactivity of the antibodies elicited against the HA globular head. 
Surprisingly, assays with the ferret antisera failed to confirm the results obtained with 
the mouse antisera. Glycosylation at site 144 alone in the non-glycosylated Neth/09 
background did not seem to increase the cross-reactivity above homologous titres 
against any of the glycosylation mutant viruses in ferrets (Table 8). However, the HI 
titre of the 144-172 glycosylated virus antiserum was equal to its homologous titre 
against rWT, Neth/09-HA144 and Neth/09-HA71-142-177. Both rWT and Neth/09-
HA144 ferret antisera remarkably lost their reactivity against the polyglycosylated 
viruses Neth/09-HA71-142, Neth/09-HA144-172 and Neth/09-HA71-142-172-177 
viruses. This indicates that in ferrets the antibodies elicited against rWT and 144 viruses 
are possibly directed more broadly around the antigenic determinants of the HA 
globular head and that these multiple glycosylations remarkably distract epitope 
recognition by HA-specific antibodies. However, cross-reactivity was sustained against 
the Neth/09-HA71-142-177, which excludes the possibility of positive correlation 
between the increasing number of glycosylation sites and the observed loss in cross-
reactivity. The homologous titres of ferret antisera were constantly higher (HI = 
320−1,280) than the titres of mouse antisera (HI = 80−320), which indicates improved 
immunogenicity of these viruses in ferrets compared to mice. Again, these results were 
largely obtained from few cross-reactivity experiments and therefore more studies are to 
be performed with ferret antisera to verify the observations. 
We were also interested in evaluating the level of IgG antibodies in mice against mutant 
viruses with multiple additional glycosylations. IgG levels were measured from mouse 
antisera by serology ELISA to assess the level of humoral response induced by the 
recombinant glycosylation mutant viruses. The IgG antibody levels were observed to be 
similar to rWT levels within the panel of viruses with 1−4 additional HA 
glycosylations, the Neth/09-HA71-142-177 virus being the least antigenic of the tested 
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viruses (Figure 15). It was confirmed that the concentration of IgG antibodies was 
independent on the variable cross-reactivity levels observed in the HI assays, which 
excludes the possibility of the broadened cross-reactivity observed for the Neth/09-
HA144 virus being due to its improved ability to induce IgG antibodies in mice. 
Evaluation of the HA expression levels in recombinant mutant viruses with 1−2 
additional HA glycosylations also confirmed that this protein is expressed at equal 
levels in mice, as determined from whole cell lysates by SDS-PAGE and Western blot 
analyses (Figure 14). 
It has been shown recently that ELISA-based microneutralisation assay is preferable to 
the standard HI assay for evaluation of influenza vaccine efficiency. It gives more 
relative information on the neutralising ability of an antiserum, whereas HI titres may 
arise from cross-reactive antibodies and therefore detect higher but non-specific 
antibody titres (Cheng et al. 2012). Within this thesis project, the inhibitory role of 
serotype-specific polyclonal serum antibodies in HA binding to its SA receptor on 
turkey RBCs was assessed by HI assays. Additionally, microneutralisation assays were 
utilised to obtain further information on the inhibitory activity of mouse and ferret 
serum nAbs against MDCK infection by Neth/09 glycosylation mutant viruses.  
Due to the limited timeline allowed for this project, microneutralisation assays were 
successfully performed solely for ferret rWT and Neth/09-HA144 antisera against their 
homologous viruses and each other. These tests showed that rWT antisera was capable 
of neutralising Neth/09-HA144 infection at equal to its homologous titre, while the 
Neth/09-HA144 antisera very surprisingly showed 4-fold decreased neutralisation of the 
rWT infection compared to its homologous titre (Table 9). However, these ferret results 
are in strong contradiction with the results obtained subsequently with mouse antisera. 
In the microneutralisation assays subsequently performed by the Medina laboratory 
following this Master’s thesis project, Neth/09-HA144 was shown to neutralise both the 
rWT and the Neth/09-HA144 at similar levels, whereas the rWT antiserum lost its 
reactivity against the Neth/09-HA144 to 4-fold lower than homologous titres (Table 9). 
No valid conclusions can be drawn from the ferret data, since the results were obtained 
from single experiments. Further re-evaluations are warranted to exclude the possibility 
of species-specific antigenicity and to standardise the ferret data with the mouse data. 
Much remains to be resolved about the 3D structure and orientation of the N-linked 
oligosaccharides. It is yet unknown how a glycan at site 144 changes the spatial 
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conformation of the antigenic site Sa and succeeds in modifying antibody recognition 
and/or binding. This may be due to cooperative action of steric hindrance and 
electrostatic repulsion or even more complex actions that involve additional changes in 
the structure of HA. The results obtained in this and previous studies suggest that 
glycosylation at site 144 is more effective at blocking the antigenic epitopes than the 
other single HA glycosylations, which could explain the observed alterations in the 
breadth of humoral response in mice. In a previous study the rescue of a mutant Neth/09 
virus carrying three additional glycosylation sites 144, 172 and 177 was not successful 
despite of several attempts, which suggests that this combination requires additional 
compensatory mutations (Medina et al. accepted). All other viruses were successfully 
rescued, although the virus with four additional glycosylations (Neth/09-HA71-142-
172-177) was shown to have a smaller plaque phenotype in MDCKs. Additionally, it is 
possible that the addition of glycosylation sites induces accessory mutations in other 
regions apart from the modified site that contribute to the overall viral antigenicity 
during multiple passages in mammalian cells.  
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7 Conclusions	
7.1 Findings	of	the	project	
It was demonstrated that the HA globular head of the natural seasonal H1N1 isolates 
acquired additional N-linked glycosylations (71, 142, 144, 172 and 179) over time, until 
the emergence of the non-glycosylated 2009 pandemic H1N1 strain. This suggests that 
the HA glycosylations take part in antigenic drift and thus have an essential role in 
influenza antigenic evolution. Based on previous evidence, it was proposed that 
glycosylation at site 144 masks the antigenic site Sa from antibody recognition and 
therefore re-directs the focus of immune response to compensatory sites in the HA 
molecule. This seems to be true for the mouse sera since all the tested WT and mutant 
sera lost their reactivity against the Neth/09-HA144 mutant virus in the cross-reactivity 
assays. Bulky oligosaccharide moieties at site 144 presumably block an essential 
antigenic epitope, which leads to deficient recognition of this virus by antibodies that 
were raised against HA molecules lacking the glycosylation site 144. Consistent with 
the previous observations from the HI assays, microneutralisation assays and human 
vaccination studies (Medina et al. accepted), the importance of site Sa modifications, 
especially the role of 144 glycosylation, for viral antigenicity was confirmed in mice.  
However, the cross-protective potential of the Neth/09-HA144 ferret antiserum was not 
verified. Further studies are warranted to draw better conclusions towards the impact of 
this glycosylation site on viral antigenicity in this animal model and to exclude the 
possibility of species-specificity. It is also important to emphasize that most of the HI 
titres that were obtained in this study with ferret antisera were from single experiments 
and therefore re-evaluation is required to confirm these preliminary data. This study is 
solely focused on assessing the breadth of polyclonal response elicited by the 
recombinant mutant Neth/09 viruses in mice and ferrets. Assays on neither the detailed 
3D molecular structure nor the effect of additional N-linked glycosylations on viral 
functionality were performed within this project. Therefore further evaluation is 
recommended to establish the overall significance of additional glycosylations in these 
animal models and eventually in humans. 
7.2 Future	prospects	
Influenza viruses infect millions of people worldwide each year and lead to huge 
economic losses due to frequent sick leaves from work, school and day care. Infection 
can be fatal in paediatric patients and the elderly and therefore prevention by 
vaccination is the first line defence mechanism. In addition to the seasonal outbreaks, 
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influenza viruses develop novel variants with pandemic potential with an interval of a 
few decades. The timing of the new pandemics cannot be predicted, which emphasises 
the need for constant alertness and preparedness for a new worldwide influenza 
epidemic. There is thrive for new vaccine applications that would allow fast, easy, safe 
and economical manufacture of broadly reactive vaccines that would provide effective 
protection against multiple influenza subtypes from various clades. In the future 
mammalian, insect and bacterial cell –based platforms will most likely take a stable 
place in the vaccine production industry and start to replace conventional embryonated 
egg –based vaccines.  
 
The role of each single HA globular head glycosylation on the level and specificity of 
the humoral immune responses remains to be specifically determined. Knowledge on 
the induction of polyclonal response mechanisms at the molecular level would provide 
important clues to future vaccine design in means of a broadly neutralising universal 
vaccine. The drawback of the current seasonal influenza vaccines is that they only 
provide protection against known seasonal isolates but fail to neutralise the arising 
variants with an altered antigenic profile due to delay in the production circle. 
Engineering HA-glycosylated recombinant viruses with an ability to elicit broad 
polyclonal response in humans provides a novel therapeutic approach for further 
development, which is also the holistic motive behind this Master’s thesis project. 
Current hopes and expectations are on new generation subunit and DNA vaccines as 
well as VLP-based vaccines that would elicit broadly cross-reactive specific humoral 
immune response in the vaccinated individuals. nAbs directed against the more 
conserved regions of the influenza virus would potentially provide protection from the 
yearly drifted variants, which would eliminate the need of vaccinating the population 
prior to each influenza season and to provide longer lasting, strong cellular and humoral 
immunity in all age groups. 
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Appendix	I	
The expression plasmid pPolI (Figure 16; described in Chapter 4.3) and the ambisense 
plasmid pDZ (Figure 17; described in Chapters 4.4.1 & 4.5) had been previously 
generated by Professor Adolfo García-Sastre (MSSM, USA). Infinite thanks for kindly 
borrowing the plasmids for the assays of this thesis. 
 
Figure 16. Map of the pPolI plasmid that was used to create the mutant pPol-HA plasmids. The 
plasmid was provided by Professor Adolfo García-Sastre (MSSM, USA). 
 
 
 
Figure 17. Map of the pDZ expression plasmid that was used for the recombinant mutant virus 
rescue and for generating the pPol-HA plasmid. The plasmid was provided by Professor Adolfo 
García-Sastre (MSSM, USA). 
